| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Editorial Board
|
|
|
|
34 |
S1 |
p. i
|
artikel
|
| 2 |
LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study
|
Kawazoe, A.
|
|
|
34 |
S1 |
p. S179
|
artikel
|
| 3 |
LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
|
Bullock, A.
|
|
|
34 |
S1 |
p. S178-S179
|
artikel
|
| 4 |
LBA-1 The Phase III Study: Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for locally advanced pancreatic cancer (TIGeR-PaC)
|
Pishvaian, M.
|
|
|
34 |
S1 |
p. S178
|
artikel
|
| 5 |
O-3 Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
|
Wyrwicz, L.
|
|
|
34 |
S1 |
p. S181
|
artikel
|
| 6 |
O-7 Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577
|
Kelly, R.
|
|
|
34 |
S1 |
p. S183
|
artikel
|
| 7 |
O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study
|
Smyth, E.
|
|
|
34 |
S1 |
p. S182-S183
|
artikel
|
| 8 |
O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
|
Li, J.
|
|
|
34 |
S1 |
p. S181-S182
|
artikel
|
| 9 |
O-9 Health-related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial
|
Prager, G.
|
|
|
34 |
S1 |
p. S184
|
artikel
|
| 10 |
O-10 Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) versus chemo (C)
|
Moehler, M.
|
|
|
34 |
S1 |
p. S185
|
artikel
|
| 11 |
O-5 Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+ gastric cancer (GC) - subgroup analyses of EORTC 1203 “INNOVATION”, a collaboration with KCSG and DUCG
|
Wagner, A.
|
|
|
34 |
S1 |
p. S182
|
artikel
|
| 12 |
O-1 Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial
|
Wainberg, Z.
|
|
|
34 |
S1 |
p. S180
|
artikel
|
| 13 |
O-12 NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal
|
Morris, V.
|
|
|
34 |
S1 |
p. S185-S186
|
artikel
|
| 14 |
O-2 Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
|
Knox, J.
|
|
|
34 |
S1 |
p. S180-S181
|
artikel
|
| 15 |
O-8 Somatic and germline heterogeneity across colorectal cancer patient characteristics: Implications for early cancer detection
|
Weitzel, J.
|
|
|
34 |
S1 |
p. S183-S184
|
artikel
|
| 16 |
O-11 The genomic landscape of appendiceal adenocarcinoma revealed by 855 whole exome sequences
|
White, M.
|
|
|
34 |
S1 |
p. S185
|
artikel
|
| 17 |
P-14 A bibliometric analysis of pd-1/pd-L1 and gastric cancer research posture over a 10-year period
|
Tian, Y.
|
|
|
34 |
S1 |
p. S18
|
artikel
|
| 18 |
P-259 Acute kidney injury after radical gastrectomy: Incidence, risk factors, and impact on prognosis
|
Zhang, B.
|
|
|
34 |
S1 |
p. S107
|
artikel
|
| 19 |
P-279 Adjuvant chemotherapy for patients with stage III colon cancer, three months vs six months. A single centre experience
|
Martin-Montalvo, G.
|
|
|
34 |
S1 |
p. S114
|
artikel
|
| 20 |
P-298 Adjuvant chemotherapy in resected lung-limited metastatic patients with colorectal cancer
|
Ziranu, P.
|
|
|
34 |
S1 |
p. S120-S121
|
artikel
|
| 21 |
P-181 Adoption of neoadjuvant immunotherapy in patients with deficient mismatch repair localized colorectal cancer: A National Cancer Database analysis
|
Kakish, H.
|
|
|
34 |
S1 |
p. S80
|
artikel
|
| 22 |
P-249 Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS/BRAF wild type metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
|
Angotti, L.
|
|
|
34 |
S1 |
p. S103-S104
|
artikel
|
| 23 |
P-236 Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS mutant metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
|
Lucchetti, J.
|
|
|
34 |
S1 |
p. S99
|
artikel
|
| 24 |
P-256 Albumin-bilirubin (ALBI) grade at 6 weeks post-diagnosis is a better prognosticator than baseline ALBI in intrahepatic cholangiocarcinoma
|
Yiu, D.
|
|
|
34 |
S1 |
p. S106
|
artikel
|
| 25 |
P-358 A machine learning approach for predicting bone metastases and its three-month prognostic risk factors in hepatocellular carcinoma patients using SEER data
|
Alkhawaldeh, I.
|
|
|
34 |
S1 |
p. S140
|
artikel
|
| 26 |
P-87 A multi-institutional observational study evaluating the efficacy of anti-epidermal growth factor antibody re-challenge in tissue RAS/BRAF wild-type metastatic colorectal cancer
|
Sawada, R.
|
|
|
34 |
S1 |
p. S44
|
artikel
|
| 27 |
P-207 Analysis of chemotherapy-induced subtype shifts in patient-derived tumoroids and parallels to functional in-vitro chemosensitivity testing in pancreatic ductal adenocarcinoma
|
Nitschke, C.
|
|
|
34 |
S1 |
p. S89
|
artikel
|
| 28 |
P-383 Analysis of microsatellite and RAS/RAF status in Tunisian colorectal cancer series
|
Douik, H.
|
|
|
34 |
S1 |
p. S148
|
artikel
|
| 29 |
P-80 Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study
|
Yamada, T.
|
|
|
34 |
S1 |
p. S42
|
artikel
|
| 30 |
P-248 Analyzing factors of resected pancreatic serous cystadenoma: A multicenter analysis
|
Lee, J.
|
|
|
34 |
S1 |
p. S103
|
artikel
|
| 31 |
P-349 An evidence-based patient resource program to improve the everyday lives of patients with metastatic gastrointestinal cancer
|
Sobrero, A.
|
|
|
34 |
S1 |
p. S136-S137
|
artikel
|
| 32 |
P-350 An improved personalized medicine network: The PLATON from GI and beyond
|
Vogel, A.
|
|
|
34 |
S1 |
p. S137
|
artikel
|
| 33 |
P-108 An interplay between immune cells and microbiota drives the spontaneous regression of colorectal polyps in familial adenomatous polyposis pig model
|
Liang, W.
|
|
|
34 |
S1 |
p. S52
|
artikel
|
| 34 |
P-104 Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)
|
Zhou, C.
|
|
|
34 |
S1 |
p. S50-S51
|
artikel
|
| 35 |
P-58 An ongoing open-label, phase 2 trial of RP2 Or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma
|
Élez, E.
|
|
|
34 |
S1 |
p. S34-S35
|
artikel
|
| 36 |
P-359 A novel concomitant NRAS and BRAF mutation in metastatic colorectal cancer
|
Douik, H.
|
|
|
34 |
S1 |
p. S140
|
artikel
|
| 37 |
P-31 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
|
Dumbrava, E.
|
|
|
34 |
S1 |
p. S24
|
artikel
|
| 38 |
P-227 A phase II trial evaluating the Activity of caBozantinib in pre-treated pAtients with metastatic COlorectal cancer (mCRC): ABACO trial
|
Martini, G.
|
|
|
34 |
S1 |
p. S96
|
artikel
|
| 39 |
P-225 Appraising the potential causal relationships between gut microbiota and colorectal cancer: A two-sample Mendelian randomization analysis
|
Liu, B.
|
|
|
34 |
S1 |
p. S95
|
artikel
|
| 40 |
P-217 A retrospective, pathologist-based assessment of immunohistochemistry assay for CLDN18.2 expression in digestive system adenocarcinoma
|
Xu, M.
|
|
|
34 |
S1 |
p. S93
|
artikel
|
| 41 |
P-316 A retrospective study of gemcitabine with nab-paclitaxel as third-line retreatment in advanced pancreatic adenocarcinoma
|
McSweeney, T.
|
|
|
34 |
S1 |
p. S126
|
artikel
|
| 42 |
P-379 ARID1A as a prognostic biomarker in gastroesophageal cancer: A genomic database analysis
|
Ricci, A.
|
|
|
34 |
S1 |
p. S146-S147
|
artikel
|
| 43 |
P-354 A single arm phase II trial of capecitabine and erlotinib in patients with advanced hepatocellular carcinoma after first-line failure (CAPER- HCC study)
|
Srinivas, S.
|
|
|
34 |
S1 |
p. S138-S139
|
artikel
|
| 44 |
P-293 A single institution experience of SBRT treatment for liver metastases and primary liver tumours
|
Oblak, I.
|
|
|
34 |
S1 |
p. S119
|
artikel
|
| 45 |
P-5 A soluble resistance related calcium binding protein (sorcin) up-regulates in the multi-drug resistant advanced gastric cancer patients
|
Ghosh, S.
|
|
|
34 |
S1 |
p. S15
|
artikel
|
| 46 |
P-112 Assessing the accuracy of CT staging for tumor and nodal staging in colon cancer
|
Yu, J.
|
|
|
34 |
S1 |
p. S54
|
artikel
|
| 47 |
P-337 Associate factors for endoscopic submucosal disection and postoperative delayed hemorrhage of colorectal neoplasm
|
Jung, Y.
|
|
|
34 |
S1 |
p. S132-S133
|
artikel
|
| 48 |
P-40 Association between HER2 expression level and long-term outcomes in surgically treated patients with gastric cancer: Impact of cancer stage
|
Enkhbat, E.
|
|
|
34 |
S1 |
p. S27
|
artikel
|
| 49 |
P-406 Association between mutated RAS status and microvascular density (MVD) in advanced colorectal cancer
|
Yaïche, H.
|
|
|
34 |
S1 |
p. S155
|
artikel
|
| 50 |
P-159 Association of acrochordons and colorectal polyps: A pilot study to identify potential genetic or viral etiology
|
Gafton, B.
|
|
|
34 |
S1 |
p. S71-S72
|
artikel
|
| 51 |
P-235 Association of stage shift and prior gastroscopy in patients with gastric cancer
|
Yang, Y.
|
|
|
34 |
S1 |
p. S99
|
artikel
|
| 52 |
P-369 Association of vascular endothelial growth factor gene polymorphisms with esophageal squamous cell cancer risk in North-West Indians: A case-control study
|
Mahajan, D.
|
|
|
34 |
S1 |
p. S143
|
artikel
|
| 53 |
P-16 Associations among patient-physician sex concordance, treatment practices, and survival outcomes in a population-based colon cancer cohort
|
Ding, P.
|
|
|
34 |
S1 |
p. S19
|
artikel
|
| 54 |
P-282 Atezolizumab and bevacizumab in the treatment of advanced hepatocellular carcinoma – a single-center experience
|
Adžić, G.
|
|
|
34 |
S1 |
p. S115
|
artikel
|
| 55 |
P-57 Atezolizumab in combination with bevacizumab in patients with unresectable HCC previously untreated with systemic therapy: Interim analysis results from phase IIIb Italian AMETHISTA trial
|
Martinelli, E.
|
|
|
34 |
S1 |
p. S34
|
artikel
|
| 56 |
P-335 AUM001 potentiates the anti-tumor activity of gemcitabine in an AsPC-1 PDAC model
|
Leong, W.
|
|
|
34 |
S1 |
p. S132
|
artikel
|
| 57 |
P-306 Bacterial lipopolysaccharide modulates immune responses in colorectal cancer
|
Permain, J.
|
|
|
34 |
S1 |
p. S123
|
artikel
|
| 58 |
P-285 Basket trials in upper gastrointestinal and hepato-pancreatico-biliary cancers – an emerging entity
|
Huddar, P.
|
|
|
34 |
S1 |
p. S116
|
artikel
|
| 59 |
P-301 Benefit of adding bevacizumab to trifluridine/tipiracil in different prognostic groups of metastatic colorectal cancer: A Portuguese exploratory analysis
|
Roque, R.
|
|
|
34 |
S1 |
p. S121-S122
|
artikel
|
| 60 |
P-311 Beyond the binary: Analysis of esophageal cancer hospitalizations in the transgender population in United States
|
Yadukumar, L.
|
|
|
34 |
S1 |
p. S125
|
artikel
|
| 61 |
P-340 Bidirectional chemotherapy for patients with gastrointestinal peritoneal carcinomatosis
|
Smolenschi, C.
|
|
|
34 |
S1 |
p. S133-S134
|
artikel
|
| 62 |
P-283 Biliary duct cancers: Clinical, epidemiological, and therapeutic features in 51 cases
|
Benamar, W.
|
|
|
34 |
S1 |
p. S115
|
artikel
|
| 63 |
P-230 Biomarkers associated with survival benefit to atezolizumab and bevacizumab for treatment of metastatic anal cancer
|
Morris, V.
|
|
|
34 |
S1 |
p. S97
|
artikel
|
| 64 |
P-134 Biomolecules with potential inhibitor of Helicobacter pylori isolated from patients with high risk of gastric cancer in Colombia
|
Pazos, A.
|
|
|
34 |
S1 |
p. S62
|
artikel
|
| 65 |
P-183 BRAF mutant metastatic colon cancer expect the unexpected: A single centre study
|
Hassan, M.
|
|
|
34 |
S1 |
p. S81
|
artikel
|
| 66 |
P-56 Brightline-2: A phase IIa/IIb, open-label trial of the MDM2–p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours
|
Macarulla, T.
|
|
|
34 |
S1 |
p. S33
|
artikel
|
| 67 |
P-109 Broaden the therapeutic opportunities for colorectal cancer: ALK inhibition benefits consensus molecular subtype 1 patients
|
Mazzeschi, M.
|
|
|
34 |
S1 |
p. S53
|
artikel
|
| 68 |
P-73 BXQ-350: A phase 1b/2 placebo-controlled, double-blind study on the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma
|
Patel, R.
|
|
|
34 |
S1 |
p. S39-S40
|
artikel
|
| 69 |
P-304 CDH1 and CTNNA1 negative hereditary diffuse gastric carcinoma cases: Genetic susceptibility variants and their potential impacts
|
Ben Aissa-Haj, J.
|
|
|
34 |
S1 |
p. S122-S123
|
artikel
|
| 70 |
P-123 CD73high biliary tract cancer (BTC) is a molecularly defined subtype with distinct clinical implications
|
Salati, M.
|
|
|
34 |
S1 |
p. S58
|
artikel
|
| 71 |
P-7 Change in CA 19-9 after 8 weeks of first-line chemotherapy as a predictor of overall survival in patients with metastatic pancreatic ductal adenocarcinoma
|
Smith, J.
|
|
|
34 |
S1 |
p. S16
|
artikel
|
| 72 |
P-144 Characterisation of gastric tumour microbiota using isolation culture methodology and a novel gastric tumour bioreactor system
|
Booth, M.
|
|
|
34 |
S1 |
p. S66
|
artikel
|
| 73 |
P-242 Characterisation of KRAS mutations in patients with metastatic colorectal cancer: A single institution experience
|
Alameda, M.
|
|
|
34 |
S1 |
p. S101
|
artikel
|
| 74 |
P-332 Characteristic and clinical outcome of localized gastric cancer; real-world data
|
AlJuhani, A.
|
|
|
34 |
S1 |
p. S131
|
artikel
|
| 75 |
P-194 Characterization of Helicobacter pylori in Colombian patients: An assessment of its evolution, antimicrobial susceptibility and virulence factors
|
Guzman, K.
|
|
|
34 |
S1 |
p. S84-S85
|
artikel
|
| 76 |
P-315 Chemotherapy treatment with mFOLFIRINOX in elderly patients with advanced pancreatic cancer
|
Basbus, l.
|
|
|
34 |
S1 |
p. S126
|
artikel
|
| 77 |
P-54 Circulating immune cells as a tool to predict benefit from atezolizumab/bevacizumab in advanced hepatocellular carcinoma (aHCC)
|
Salani, F.
|
|
|
34 |
S1 |
p. S32
|
artikel
|
| 78 |
P-27 Circulating neural growth factor in pancreatic cancer adenocarcinoma
|
Garajová, I.
|
|
|
34 |
S1 |
p. S23
|
artikel
|
| 79 |
P-96 Circulating tumor-derived DNA (ctDNA) clearance in patients with locally advanced rectal cancer treated with multimodal treatment
|
Gervaso, L.
|
|
|
34 |
S1 |
p. S48
|
artikel
|
| 80 |
P-8 Circulating tumor DNA could have impact on risk assessment and personalizing adjuvant therapy in localized colon cancer
|
Elbaiomy, M.
|
|
|
34 |
S1 |
p. S16
|
artikel
|
| 81 |
P-297 Clinical characteristics and outcomes of patients with hepatocellular carcinoma treated at a large multidisciplinary clinic in Saudi Arabia
|
Alshammari, K.
|
|
|
34 |
S1 |
p. S120
|
artikel
|
| 82 |
P-198 Clinical characteristics of metastatic colorectal cancer with EGFR amplification: A single-center experience
|
Kim, S.
|
|
|
34 |
S1 |
p. S86
|
artikel
|
| 83 |
P-197 Clinical outcomes in patients with Krukenberg tumors from colorectal cancer
|
Ostowari, A.
|
|
|
34 |
S1 |
p. S86
|
artikel
|
| 84 |
P-23 Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study
|
Kato, T.
|
|
|
34 |
S1 |
p. S21-S22
|
artikel
|
| 85 |
P-200 Clinical outcomes of T4 and/or N2 rectal cancer after neoadjuvant chemoradiotherapy: A retrospective study
|
Barthwal, M.
|
|
|
34 |
S1 |
p. S87
|
artikel
|
| 86 |
P-118 Clinical significance of primary tumor sites and epithelial tumor markers in patients with unresectable/recurrent gastrointestinal neuroendocrine carcinoma treated with combined chemotherapy with irinotecan and cisplatin
|
Fukuda, K.
|
|
|
34 |
S1 |
p. S56
|
artikel
|
| 87 |
P-116 Clinical utility of circulating tumor DNA (ctDNA) in patients with early/resected biliary tract cancer (BTC)
|
Yu, J.
|
|
|
34 |
S1 |
p. S55-S56
|
artikel
|
| 88 |
P-178 Clinico-epidemiological and therapeutic profile of pancreatic cancer: Oran center’s experience
|
Zeroual, S.
|
|
|
34 |
S1 |
p. S79
|
artikel
|
| 89 |
P-324 Clinicopathological characteristics of patients with colorectal cancer lung metastasis under different conditions
|
Xu, G.
|
|
|
34 |
S1 |
p. S128-S129
|
artikel
|
| 90 |
P-257 Clinicopathological characteristics, therapeutic strategy and prognosis analysis of 501 cases of gastric neuroendocrine neoplasms in a single center
|
Zhang, B.
|
|
|
34 |
S1 |
p. S106
|
artikel
|
| 91 |
P-286 Clinicopathological profile and outcomes in locally advanced rectal cancer with major pathological response following neoadjuvant therapy
|
Gammoudi, A.
|
|
|
34 |
S1 |
p. S116
|
artikel
|
| 92 |
P-70 Co-infection with Helicobacter pylori and Epstein-Barr virus occurs at early stage of gastric carcinogenesis
|
Lim, S.
|
|
|
34 |
S1 |
p. S38-S39
|
artikel
|
| 93 |
P-351 Colon cancer in young patients – real-world data from a single center review
|
Montenegro, M.
|
|
|
34 |
S1 |
p. S137-S138
|
artikel
|
| 94 |
P-151 Colorectal adenocarcinoma as second primary cancer in Latin American population
|
Calderillo-Ruiz, G.
|
|
|
34 |
S1 |
p. S69
|
artikel
|
| 95 |
P-105 COLSTAR study: Safety data on the first cohort of patients from the safety lead-in part of the study
|
Ciardiello, F.
|
|
|
34 |
S1 |
p. S51
|
artikel
|
| 96 |
P-327 Comparison of clinicopathological and molecular features of two rare entities: Appendiceal carcinoma and small bowel adenocarcinoma
|
Vega-Cano, K.
|
|
|
34 |
S1 |
p. S129
|
artikel
|
| 97 |
P-352 Comparison of KRAS status between primary colorectal tumor and metastasis or recurrent tumor
|
Douik, H.
|
|
|
34 |
S1 |
p. S138
|
artikel
|
| 98 |
P-247 Comparison of overall survival of malignant gastric neuroendocrine tumor with gastric adenocarcinoma: A propensity score matching study
|
Zhang, B.
|
|
|
34 |
S1 |
p. S103
|
artikel
|
| 99 |
P-252 Comparison of second-line treatment after GEM/nab-PTX therapy for metastatic pancreatic cancer
|
Takeshita, K.
|
|
|
34 |
S1 |
p. S104-S105
|
artikel
|
| 100 |
P-199 Comparison of treatment outcomes of regorafenib for patients with metastatic colorectal cancer by era: A propensity-score matched analysis
|
Ogata, T.
|
|
|
34 |
S1 |
p. S86-S87
|
artikel
|
| 101 |
P-224 Complete pathological response after short course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer (LARC): Real-world outcome and toxicity
|
Dhib, D.
|
|
|
34 |
S1 |
p. S95
|
artikel
|
| 102 |
P-142 Completion of genetic testing and incidence of pathogenic germline mutation among patients with early-onset colorectal cancer, a single institution retrospective analysis
|
Storandt, M.
|
|
|
34 |
S1 |
p. S65
|
artikel
|
| 103 |
P-408 Costa Rica, an example of the Americas in the implementation of an innovative organized colorectal screening program during 2017–2022
|
Sanchez, A.
|
|
|
34 |
S1 |
p. S156
|
artikel
|
| 104 |
P-420 Could a reduced dose of m FOLFORINOX represent safe and efficacious start-off in advanced pancreatic cancer? A retrospective evaluation of real-world data
|
Saad, E.
|
|
|
34 |
S1 |
p. S159-S160
|
artikel
|
| 105 |
P-376 CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors
|
Obermannová, R.
|
|
|
34 |
S1 |
p. S145-S146
|
artikel
|
| 106 |
P-317 CT radiomics for the preoperative prediction of molecular subtypes in gastric stromal tumor
|
Yin, X.
|
|
|
34 |
S1 |
p. S126
|
artikel
|
| 107 |
P-125 Current practices in metastatic colorectal cancer: Results from the real-world screening and consensus based on practices and evidence (SCOPE) program in gastrointestinal cancers
|
Prager, G.
|
|
|
34 |
S1 |
p. S58-S59
|
artikel
|
| 108 |
P-115 Cytoreductive surgery and HIPEC in the treatment of peritoneal carcinomatosis: The experience in a tertiary university hospital
|
Perez, J. Chamorro
|
|
|
34 |
S1 |
p. S55
|
artikel
|
| 109 |
PD-24 A novel molecular subtype for Chinese stage II-III colorectal cancer based on multi-center and large sample size data
|
Xu, M.
|
|
|
34 |
S1 |
p. S10-S11
|
artikel
|
| 110 |
PD-9 Anti-HER2 therapy following ctDNA-identified ERBB2 amplification for patients with advanced gastric cancer: Exploration of real-world outcomes and resistance mechanisms
|
Chakrabarti, S.
|
|
|
34 |
S1 |
p. S4
|
artikel
|
| 111 |
PD-16 Atezolizumab plus bevacizumab is associated with improved survival outcomes in HCC patients with Child-Pugh B dysfunction compared to best supportive therapy
|
Fulgenzi, C.
|
|
|
34 |
S1 |
p. S7
|
artikel
|
| 112 |
PD-11 Clinical and molecular characterization of oligometastatic lung disease in resected pancreatic cancer
|
Tissera, N.
|
|
|
34 |
S1 |
p. S5
|
artikel
|
| 113 |
PD-2 Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies
|
Veas, J.
|
|
|
34 |
S1 |
p. S1
|
artikel
|
| 114 |
PD-23 Comprehensive survey of AACR GENIE cBioPortal database of receptor tyrosine kinase fusion in colorectal carcinoma identified high co-occurring genomic alterations in NTRK1 & RET fusion-positive CRC
|
Lee, A.
|
|
|
34 |
S1 |
p. S10
|
artikel
|
| 115 |
PD-29 Could molecular profiling be helpful in daily practice in the treatment of anal carcinoma?
|
Smolenschi, C.
|
|
|
34 |
S1 |
p. S13
|
artikel
|
| 116 |
PD-4 Deep learning of pancreatic cancer histopathology images predicts recurrence after surgery
|
Wong, A.
|
|
|
34 |
S1 |
p. S2
|
artikel
|
| 117 |
PD-25 Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colorectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study
|
Prager, G.
|
|
|
34 |
S1 |
p. S11
|
artikel
|
| 118 |
PD-26 Efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal versus gastric cancers: A large, multicenter, cohort study
|
Mazzoli, G.
|
|
|
34 |
S1 |
p. S11-S12
|
artikel
|
| 119 |
P-218 Definitions of oligometastatic pancreatic cancer: A systematic review
|
Leonhardt, C.
|
|
|
34 |
S1 |
p. S93
|
artikel
|
| 120 |
P-319 Delay in pancreatic cancer diagnosis and treatment: Call to action
|
Escorza-Calzada, S.
|
|
|
34 |
S1 |
p. S127
|
artikel
|
| 121 |
P-37 Delineating the driving role of the YAP-FOXP4-SOX12 axis in gastric carcinogenesis by maintaining the stemness
|
Liu, X.
|
|
|
34 |
S1 |
p. S26
|
artikel
|
| 122 |
P-184 Demographic and clinicopathologic factors in patients with hepatocellular carcinoma in Latin American population
|
Calderillo-Ruiz, G.
|
|
|
34 |
S1 |
p. S81
|
artikel
|
| 123 |
P-262 Descriptive study of bile duct tumors in a province
|
Madrigal, L. Fernández
|
|
|
34 |
S1 |
p. S108
|
artikel
|
| 124 |
P-135 Detection of RAS gene mutations in patients with metastatic colorectal cancer during cetuximab-based first-line treatment and survival of the patients in relation to changes in RAS gene status
|
Stresko, M.
|
|
|
34 |
S1 |
p. S63
|
artikel
|
| 125 |
P-44 Developing small molecules to disrupt IL-17RB and MLK4 interaction for pancreatic cancer treatment
|
Hu, C.
|
|
|
34 |
S1 |
p. S29
|
artikel
|
| 126 |
P-366 Development and validation of a predictive tool for oesophageal cancer patients: A Moroccan-based study
|
Tafenzi, H. Abdelilah
|
|
|
34 |
S1 |
p. S142
|
artikel
|
| 127 |
PD-21 Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in metastatic colorectal cancer (mCRC) patients
|
Carullo, M.
|
|
|
34 |
S1 |
p. S9
|
artikel
|
| 128 |
PD-19 Finnish population-based metastatic colorectal cancer data collection study – comparison with the prospective RAXO study
|
Heervä, E.
|
|
|
34 |
S1 |
p. S8-S9
|
artikel
|
| 129 |
PD-8 HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2+ advanced stomach cancer – correlation of the antibody responses and clinical outcome
|
Tobias, J.
|
|
|
34 |
S1 |
p. S4
|
artikel
|
| 130 |
P-331 Differentiating subcentimeter lung metastases in colorectal cancer patients by radiomics and deep learning approaches: A multicenter study
|
Gao, X.
|
|
|
34 |
S1 |
p. S130-S131
|
artikel
|
| 131 |
P-171 Digital image analysis of Ki67 heterogeneity of pancreatic neuroendocrine neoplasms with or without liver metastasis
|
Zhang, M.
|
|
|
34 |
S1 |
p. S76
|
artikel
|
| 132 |
P-328 Dihydropyrimidine dehydrogenase deficiency frequency and its impact on 5-fluorouracil (5-FU) based chemotherapy toxicity
|
Lakhdari, H.
|
|
|
34 |
S1 |
p. S130
|
artikel
|
| 133 |
PD-28 Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis
|
André, T.
|
|
|
34 |
S1 |
p. S12-S13
|
artikel
|
| 134 |
PD-18 Maintenance proton pump inhibitor usage and risk of colorectal cancer: A population-based Swedish cohort study
|
Liu, Q.
|
|
|
34 |
S1 |
p. S8
|
artikel
|
| 135 |
PD-13 Modified albumin-bilirubin grade after curative treatment predicts the risk of late intrahepatic recurrence of hepatocelluar carcinoma
|
Yu, J.
|
|
|
34 |
S1 |
p. S6
|
artikel
|
| 136 |
PD-5 MONEO: Phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC)
|
Alsina, M.
|
|
|
34 |
S1 |
p. S2-S3
|
artikel
|
| 137 |
PD-17 Multicentric prospective study assessing clinical benefit of targeted treatment for patients with biliary tract cancers
|
Niger, M.
|
|
|
34 |
S1 |
p. S7-S8
|
artikel
|
| 138 |
P-371 Docetaxel-based perioperative chemotherapy in gastric and gastroesophageal (GEJ) adenocarcinomas – a real world experience from a tertiary cancer centre in India
|
Khan, A.
|
|
|
34 |
S1 |
p. S144
|
artikel
|
| 139 |
P-39 Does resection in patients of metastatic carcinoma of gall bladder who turn resectable after palliative chemotherapy offer any survival advantage?
|
Parasar, K.
|
|
|
34 |
S1 |
p. S27
|
artikel
|
| 140 |
P-422 Does the non-lifting sign predict the depth of invasion in early gastric cancer?
|
Kim, B.
|
|
|
34 |
S1 |
p. S160
|
artikel
|
| 141 |
PD-10 Organoids as tools for functional precision oncology in advanced pancreatic cancer
|
Boileve, A.
|
|
|
34 |
S1 |
p. S4-S5
|
artikel
|
| 142 |
PD-7 Osemitamab plus capecitabine and oxaliplatin (CAPOX) as the first-line treatment of advanced G/GEJ cancer – updated efficacy data per claudin 18.2 expression level from study TranStar102/TST001-1002-cohort C
|
Shen, L.
|
|
|
34 |
S1 |
p. S3
|
artikel
|
| 143 |
P-47 Double-blind placebo-controlled randomized clinical trial on the concurrent use of crocin during chemoradiation of esophageal squamous cell carcinoma
|
Javadinia, S.
|
|
|
34 |
S1 |
p. S29-S30
|
artikel
|
| 144 |
PD-6 Perioperative immunochemotherapy (mDCF + avelumab) in locally advanced gastroesophageal adenocarcinoma: A phase II trial. Correlation of response with molecular and imaging test results
|
Alcindor, T.
|
|
|
34 |
S1 |
p. S3
|
artikel
|
| 145 |
PD-3 Prognosis evaluation and molecular typing of gastric neuroendocrine tumors based on proteomics and non-negative matrix factorization model
|
Zhang, B.
|
|
|
34 |
S1 |
p. S1-S2
|
artikel
|
| 146 |
PD-1 Prognostic effect of immunohistochemically classified molecular subtypes in gastric cancer
|
Brodkin, J.
|
|
|
34 |
S1 |
p. S1
|
artikel
|
| 147 |
P-204 DPYD gene variants and chemotherapy-induced toxicity in Omani patients with gastrointestinal tumors
|
Ghoche, A.
|
|
|
34 |
S1 |
p. S88
|
artikel
|
| 148 |
PD-22 RAS-mutations in population-based and real-life metastatic colorectal cancer cohorts
|
Osterlund, E.
|
|
|
34 |
S1 |
p. S9-S10
|
artikel
|
| 149 |
PD-15 Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments
|
Persano, M.
|
|
|
34 |
S1 |
p. S6-S7
|
artikel
|
| 150 |
PD-20 Short- and long-term survival among elderly colorectal cancer patients in Finland 2006–2015: A nationwide registry study
|
Hukkinen, T.
|
|
|
34 |
S1 |
p. S9
|
artikel
|
| 151 |
PD-14 TERT-associated DNA polymerases genes link CAF and CD8+ T cells to improve immunotherapy response rate across multiple cancers
|
Luo, Z.
|
|
|
34 |
S1 |
p. S6
|
artikel
|
| 152 |
PD-27 The use of pre-operative systemic oxaliplatin or irinotecan doublet chemotherapy in colorectal cancer peritoneal metastases (CRPM): Results from a single UK peritoneal tumour centre
|
Tinsley, N.
|
|
|
34 |
S1 |
p. S12
|
artikel
|
| 153 |
PD-12 Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort
|
Lansbergen, M.
|
|
|
34 |
S1 |
p. S5
|
artikel
|
| 154 |
P-41 Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data
|
Rimini, M.
|
|
|
34 |
S1 |
p. S28
|
artikel
|
| 155 |
P-398 Early chemo- and immuno-related toxicities in previously untreated colorectal cancer patients according to age: A retrospective single-centre study
|
Filippi, B.
|
|
|
34 |
S1 |
p. S152
|
artikel
|
| 156 |
P-169 Early-onset biliary tract cancer: An overview of clinical presentation, risk factors, molecular profile and outcome in a multicentric Italian cohort
|
Vivaldi, C.
|
|
|
34 |
S1 |
p. S75-S76
|
artikel
|
| 157 |
P-239 Effectiveness and safety of palliative surgical interventions for bowel obstruction in advanced staged colorectal cancer: A systematic review and network meta-analysis
|
Vo, N.
|
|
|
34 |
S1 |
p. S100
|
artikel
|
| 158 |
P-368 Efficacacy of trifluridine/tipiracil according to extended RAS evaluation: A multicenter retrospective analysis
|
Caira, G.
|
|
|
34 |
S1 |
p. S143
|
artikel
|
| 159 |
P-180 Efficacy and safety of anti-PD1 agents in patients with advanced GI malignancies: Real-world data
|
Luis, S. Montenegro
|
|
|
34 |
S1 |
p. S80
|
artikel
|
| 160 |
P-156 Efficacy and safety of cadonilimab combined with FLOT regimen as a neoadjuvant therapy for locally advanced gastric/gastroesophageal junction adenocarcinoma: A prospective, multicenter, open-label, single-arm phase II study
|
Long, B.
|
|
|
34 |
S1 |
p. S70-S71
|
artikel
|
| 161 |
P-164 Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POLƐ)-mutated solid tumours in the GARNET study
|
Samuel, L.
|
|
|
34 |
S1 |
p. S73-S74
|
artikel
|
| 162 |
P-269 Efficacy and safety of doublet adjuvant chemotherapy for elderly patients with stage III colorectal cancer
|
Silva, S.
|
|
|
34 |
S1 |
p. S110-S111
|
artikel
|
| 163 |
P-146 Efficacy and safety of FLOT combined with apatinib and sintilimab as a neoadjuvant therapy regimen for locally advanced gastric or gastroesophageal junction adenocarcinoma: An open-lable, single-arm, phase II study
|
Zhou, H.
|
|
|
34 |
S1 |
p. S66-S67
|
artikel
|
| 164 |
P-69 Efficacy and safety of surufatinib in intrahepatic cholangiocarcinoma: Preliminary results of a real-world study
|
Zhang, Z.
|
|
|
34 |
S1 |
p. S38
|
artikel
|
| 165 |
P-210 Efficacy and tolerability of cetuximab 750 mg/m2 every three weeks in metastatic colorectal cancer
|
Aseafan, M.
|
|
|
34 |
S1 |
p. S90
|
artikel
|
| 166 |
P-360 Efficacy of regorafenib according to extended RAS evaluation: A multicenter retrospective analysis
|
Trovato, G.
|
|
|
34 |
S1 |
p. S140-S141
|
artikel
|
| 167 |
P-120 Efficacy of systemic therapy for advanced hepatocellular carcinoma based on etiology: A systematic review and network meta-analysis
|
Wong, C.
|
|
|
34 |
S1 |
p. S57
|
artikel
|
| 168 |
P-186 Efficacy of the combined chemotherapy regimens in elderly patients with advanced pancreatic cancer
|
Manukyan, M.
|
|
|
34 |
S1 |
p. S82
|
artikel
|
| 169 |
P-145 Efficacy, safety, and predictors of fruquintinib plus PD-1 in refractory MSS metastatic colorectal cancer in a real-world setting
|
Yang, X.
|
|
|
34 |
S1 |
p. S66
|
artikel
|
| 170 |
P-206 Endoscopic prediction of depth of tumor invasion in early gastric cancer in the upper third of the stomach
|
Moon, H.
|
|
|
34 |
S1 |
p. S89
|
artikel
|
| 171 |
P-243 Endothelin-1 promotes growth and metastasis of esophageal squamous cell carcinoma
|
Jayaraman, S.
|
|
|
34 |
S1 |
p. S101-S102
|
artikel
|
| 172 |
P-97 Enhanced recovery protocol (ERAS) in colorectal surgery and its effect on the survival of patients in the medium term (3 years)
|
Cuadrado-García, A.
|
|
|
34 |
S1 |
p. S48
|
artikel
|
| 173 |
P-110 Epidemiological and clinicopathological features of early- (EOPC) and late-onset pancreatic cancer (LOPC) patients (pts): A mono-institutional retrospective analysis
|
Bensi, M.
|
|
|
34 |
S1 |
p. S53
|
artikel
|
| 174 |
P-385 Epidemiological, clinical and therapeutic profile of gastric cancer
|
Merair, N.
|
|
|
34 |
S1 |
p. S148
|
artikel
|
| 175 |
P-263 Epidemiology and characteristics of low or normal AFP vs high AFP in hepatocellular carcinoma – retrospective experience in a tertiary care institute
|
A, A.
|
|
|
34 |
S1 |
p. S108
|
artikel
|
| 176 |
P-244 Epidemiology and management of locally advanced and metastatic colorectal cancer RAS wild type: A retrospective study of 70 patients
|
Boudinar, F.
|
|
|
34 |
S1 |
p. S102
|
artikel
|
| 177 |
P-163 Epidemiology and outcome of gastrointestinal cancers in adolescents and young adults: Experience from South India
|
Pathak, S.
|
|
|
34 |
S1 |
p. S73
|
artikel
|
| 178 |
P-101 Epidemiology of gastric cancer in Georgia addressing sex differences – 5-year analyses of cancer registry
|
Esakia, T.
|
|
|
34 |
S1 |
p. S49-S50
|
artikel
|
| 179 |
P-51 Epigenome-wide DNA methylation profiling identifies the TNXB gene as a potential epigenetic candidate for colorectal cancer prevention
|
Boughanem, H.
|
|
|
34 |
S1 |
p. S31
|
artikel
|
| 180 |
P-88 Epithelial-to-mesenchymal transition: An emerging prognostic tool in resectable pancreatic cancer, a retrospective study
|
Machmouchi, A.
|
|
|
34 |
S1 |
p. S44-S45
|
artikel
|
| 181 |
P-141 EPIYA motif analysis of Helicobacter pylori isolated from Colombian patients with precursor lesions of gastric cancer
|
Guzman, K.
|
|
|
34 |
S1 |
p. S65
|
artikel
|
| 182 |
P-330 ERBB2 mutations in metastatic colorectal cancer: From clinicopatholgical features to potential treatment implications in a real-world cohort
|
Vaghi, C.
|
|
|
34 |
S1 |
p. S130
|
artikel
|
| 183 |
P-237 Esophageal microbiome correlates with post-esophagectomy anastomotic leak in cancer patients
|
Naddaf, R.
|
|
|
34 |
S1 |
p. S99-S100
|
artikel
|
| 184 |
P-250 Establishment and validation of a nomogram prognostic prediction model for 490 gastric neuroendocrine neoplasms in a single center
|
Zhang, B.
|
|
|
34 |
S1 |
p. S104
|
artikel
|
| 185 |
P-258 Establishment and validation of a predictive model for lymph node metastasis of gastric neuroendocrine neoplasms
|
Zhang, B.
|
|
|
34 |
S1 |
p. S106-S107
|
artikel
|
| 186 |
P-168 Estrogen signaling shapes a tumor suppressive stroma in pancreatic cancer
|
Manoukian, P.
|
|
|
34 |
S1 |
p. S75
|
artikel
|
| 187 |
P-78 Evaluation of nutritional status in digestive oncology (study about 167 cases)
|
Houda, A.
|
|
|
34 |
S1 |
p. S41
|
artikel
|
| 188 |
P-131 Evaluation of predictive factors of toxicity of chemotherapy with FOLFIRINOX in patients treated for pancreatic adenocarcinoma
|
Eid, R.
|
|
|
34 |
S1 |
p. S61-S62
|
artikel
|
| 189 |
P-72 Evaluation of the prognostic role of neutrophil-lymphocyte ratio in metastatic colorectal cancer
|
Ben Kridis, W.
|
|
|
34 |
S1 |
p. S39
|
artikel
|
| 190 |
P-113 Evidence for early detection of metastatic variants and tumour evolution in ctDNA of patients with oesophageal adenocarcinoma
|
Openshaw, M.
|
|
|
34 |
S1 |
p. S54
|
artikel
|
| 191 |
P-396 Exploration of metabolomic markers for esophageal squamous cancer based on the Linxian Nutrition Intervention Trial population
|
Wang, X.
|
|
|
34 |
S1 |
p. S152
|
artikel
|
| 192 |
P-389 Exploring the prognostic value in methylation markers in early detection of hepatocellular carcinoma
|
Furman, A.
|
|
|
34 |
S1 |
p. S149-S150
|
artikel
|
| 193 |
P-122 Expression of apurinic/apyrimidinic endonuclease 1 in colorectal cancer and its relation to tumor progression and prognosis
|
Oh, H.
|
|
|
34 |
S1 |
p. S57-S58
|
artikel
|
| 194 |
P-173 Extended molecular profiling in patients with biliary tract cancers: Impact of the BRCAness phenotype in patients management
|
Genovesi, V.
|
|
|
34 |
S1 |
p. S77
|
artikel
|
| 195 |
P-410 Factors affecting progression-free survival (PFS) for patients with metastatic colorectal cancer (mCRC) receiving regorafenib or for patients after re-challenge previously effective chemotherapy (CT) regimens in third or following lines
|
Kuzmina, E.
|
|
|
34 |
S1 |
p. S156
|
artikel
|
| 196 |
P-157 Factors associated with success rates and complications of metal stent insertion for left-sided colorectal cancer obstruction
|
Han, B.
|
|
|
34 |
S1 |
p. S71
|
artikel
|
| 197 |
P-121 Factors associated with technical difficulty in colorectal endoscopic submucosal dissection
|
Oh, H.
|
|
|
34 |
S1 |
p. S57
|
artikel
|
| 198 |
P-211 Factors predicting nodal spread in curatively resected gastric cancer – analysis from a tertiary care center in India
|
Simha, A.
|
|
|
34 |
S1 |
p. S90-S91
|
artikel
|
| 199 |
P-79 Feasibility and toxicity of hypofractionated radiotherapy (5x5 Gy) with a simultaneous integrated boost (5x6 Gy) in locally advanced rectal cancer: 2023 update
|
Temnyk, M.
|
|
|
34 |
S1 |
p. S41-S42
|
artikel
|
| 200 |
P-117 Feasibility of tumor informed circulating tumor DNA in neoadjuvant rectal cancer
|
Malla, M.
|
|
|
34 |
S1 |
p. S56
|
artikel
|
| 201 |
P-201 First large cohort in Latin America of CCR BRAF V600E mutated. Real world data
|
Catani, G.
|
|
|
34 |
S1 |
p. S87
|
artikel
|
| 202 |
P-165 First-line treatment with CET/PAN vs. BEV in elderly patients with RAS WT mCRC: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
|
Yamamoto, K.
|
|
|
34 |
S1 |
p. S74
|
artikel
|
| 203 |
P-153 Focus on RAS codon 61 mutations in metastatic colorectal cancer (mCRC): A retrospective analysis
|
Schietroma, F.
|
|
|
34 |
S1 |
p. S69
|
artikel
|
| 204 |
P-275 FOLFOX versus FOLFIRI as second-line treatment after cisplatin-gemcitabine in patients with advanced biliary tract cancers
|
Nichetti, F.
|
|
|
34 |
S1 |
p. S113
|
artikel
|
| 205 |
P-240 Frequency and management of trifluridine/tipiracil (FTD/TPI) + bevacizumab (BEV)-associated neutropenia in patients with refractory metastatic colorectal cancer (mCRC) in real-world practice
|
Lago, N. Martínez
|
|
|
34 |
S1 |
p. S100-S101
|
artikel
|
| 206 |
P-22 Frequency of dihydropyrimidine dehydrogenase (DPD) deficiency detection and adverse events in patients receiving fluoropyrimidine-based therapy in a pancreatic and biliary tract cancer cohort
|
Wilson, E.
|
|
|
34 |
S1 |
p. S21
|
artikel
|
| 207 |
P-1 Gastric cancer: Artificial intelligence, complex system analysis and simulation for best management
|
Kshivets, O.
|
|
|
34 |
S1 |
p. S14
|
artikel
|
| 208 |
P-393 Gastric cancer metastasis patterns and racial disparities: SEER database population study 2010-2019
|
El-Sakka, A.A.
|
|
|
34 |
S1 |
p. S151
|
artikel
|
| 209 |
P-414 Gastric cancer risk factors knowledge in Mexican population. LEGACy 3A
|
Ruiz-Garcia, E.
|
|
|
34 |
S1 |
p. S158
|
artikel
|
| 210 |
P-347 Gastrointestinal microbiome association with health status in Latvian population reveals significant shifts in gastrointestinal cancer patients at taxonomical and functional level
|
Ustinova, M.
|
|
|
34 |
S1 |
p. S136
|
artikel
|
| 211 |
P-21 GastroPanel: A blood test to triage dyspeptic patients with atrophic gastritis at risk of developing gastric adenocarcinoma
|
Papadia, C.
|
|
|
34 |
S1 |
p. S20-S21
|
artikel
|
| 212 |
P-76 Genomic and transcriptomic characterization of pancreatic neuroendocrine tumors reveals novel therapeutic candidates
|
Azmi, A.
|
|
|
34 |
S1 |
p. S40-S41
|
artikel
|
| 213 |
P-273 Genomic signatures associated with aggressive histology and decreased overall survival in neuroendocrine malignancies
|
Farha, N.
|
|
|
34 |
S1 |
p. S112
|
artikel
|
| 214 |
P-46 GIT carcinoids and the risk of multiple primary GIT tumors
|
Ellaithy, A.
|
|
|
34 |
S1 |
p. S29
|
artikel
|
| 215 |
P-185 Global and regional trends in the incidence and mortality of Colorectal Cancer (CRC): Analysis of data from the GLOBOCAN database and SEER database
|
Desai, K.
|
|
|
34 |
S1 |
p. S81-S82
|
artikel
|
| 216 |
P-191 Helicobacter pylori ancestors associated to gastric microbiota dysbiosis in Colombian patients with gastric cancer precursor lesions
|
Pazos, A.
|
|
|
34 |
S1 |
p. S83-S84
|
artikel
|
| 217 |
P-36 Hepatocellular carcinoma: Trend in time and age-groups in the United States – a SEER registry analysis
|
Fatima, I.
|
|
|
34 |
S1 |
p. S26
|
artikel
|
| 218 |
P-148 Her2 positive as the main biomarker for overall survival of advanced gastric adenocarcinoma: Latin American reality and challenges
|
Diaz, C.
|
|
|
34 |
S1 |
p. S67-S68
|
artikel
|
| 219 |
P-119 HGCSG 1803: Single-arm phase Ⅱ study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment
|
Sawada, K.
|
|
|
34 |
S1 |
p. S56-S57
|
artikel
|
| 220 |
P-62 High titer of anti-Helicobacter pylori antibody as a predictor for diffuse type gastric cancer
|
Cho, S.
|
|
|
34 |
S1 |
p. S36
|
artikel
|
| 221 |
P-150 Hispanic/Latino patients with metastatic gastric adenocarcinoma: Impact of single metastasis in overall survival
|
Diaz, C.
|
|
|
34 |
S1 |
p. S68-S69
|
artikel
|
| 222 |
P-299 Histopathological findings following preoperative treatment and the outcomes of gastric cancer patients treated with perioperative FLOT
|
Martins, J.
|
|
|
34 |
S1 |
p. S121
|
artikel
|
| 223 |
P-42 How to improve outcome in high-risk stage III colon cancer with dMMR gene
|
Abdelsalam, Y.
|
|
|
34 |
S1 |
p. S28
|
artikel
|
| 224 |
P-133 Human susceptibility biomarkers associated to gastric cancer risk in Colombia populations
|
Pazos, A.
|
|
|
34 |
S1 |
p. S62
|
artikel
|
| 225 |
P-86 Hypo-albuminemia as a tumor-related prognostic factor in metastatic pancreatic adenocarcinoma
|
Venturino, A.
|
|
|
34 |
S1 |
p. S44
|
artikel
|
| 226 |
P-67 Immune cell and microbiome contributions to radiotherapy response in rectal cancer
|
Purcell, R.
|
|
|
34 |
S1 |
p. S37-S38
|
artikel
|
| 227 |
P-320 Immune checkpoint inhibitors (ICIs) vs chemotherapy as 3rd-line regimen in patients with advanced gastric or esophageal (G/E) adenocarcinoma: A comparative study
|
Saeed, A.
|
|
|
34 |
S1 |
p. S127
|
artikel
|
| 228 |
P-280 Impact of comprehensive geriatric assessment in elderly patients with colorectal cancer
|
Miraoui, D.
|
|
|
34 |
S1 |
p. S114
|
artikel
|
| 229 |
P-313 Impact of COVID-19 on national trends of hospitalization and outcomes in pancreatic cancer patients presenting with venous thromboembolism in the United States
|
Yadukumar, L.
|
|
|
34 |
S1 |
p. S125
|
artikel
|
| 230 |
P-82 Impact of COVID-19 pandemic on metastatic colorectal cancer outcomes
|
Mavic, M. Pavlovic
|
|
|
34 |
S1 |
p. S43
|
artikel
|
| 231 |
P-229 Impact of nutritional status in overall survival of colorectal cancer Latin American patients
|
Camargo, D. Pérez
|
|
|
34 |
S1 |
p. S97
|
artikel
|
| 232 |
P-346 Impact of preoperative radiotherapy on lymph node status in patients with rectal cancer: Experience of the radiotherapy department–EHSO Emir Abdelkader-Oran
|
Cheriguene, M.
|
|
|
34 |
S1 |
p. S136
|
artikel
|
| 233 |
P-68 Impact of specimens and fixation status on HER2 assessment in the treatment of advanced gastric cancer (HER_WEEKEND study)
|
Nakamura, M.
|
|
|
34 |
S1 |
p. S38
|
artikel
|
| 234 |
P-388 Impact of the curative treatment of colorectal liver metastases
|
Fendri, S.
|
|
|
34 |
S1 |
p. S149
|
artikel
|
| 235 |
P-417 Impact of tumor location on clinicohistological profile and oncological outcomes in Tunisian population
|
Chahed, M.
|
|
|
34 |
S1 |
p. S158-S159
|
artikel
|
| 236 |
P-17 Impacts of patient-reported non-hormonal symptoms on outcomes of patients with neuroendocrine neoplasms (NENs)
|
Abdel-Rahman, O.
|
|
|
34 |
S1 |
p. S19
|
artikel
|
| 237 |
P-136 Increased healthcare costs due to diagnostic imaging services following false elevation of plasma chromogranin A and 24-hour urinary 5-hydroxyindoleacetic acid: A quality improvement project
|
Laderian, B.
|
|
|
34 |
S1 |
p. S63
|
artikel
|
| 238 |
P-395 Induction chemotherapy followed by response evaluation and esophagectomy for advanced esophageal cancer
|
van der Zijden, C.
|
|
|
34 |
S1 |
p. S151-S152
|
artikel
|
| 239 |
P-372 Inflammatory status as a predictor of resectability in borderline resectable pancreatic cancer
|
Goncalves, M.
|
|
|
34 |
S1 |
p. S144
|
artikel
|
| 240 |
P-195 Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study
|
Signorelli, C.
|
|
|
34 |
S1 |
p. S85
|
artikel
|
| 241 |
P-166 Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma
|
Pretta, A.
|
|
|
34 |
S1 |
p. S74
|
artikel
|
| 242 |
P-373 Insights of the prevalence of KRAS mutations in a real life population cohort of colorectal cancer based in north of Portugal
|
Falcão, M.
|
|
|
34 |
S1 |
p. S144-S145
|
artikel
|
| 243 |
P-231 Interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2)
|
Weinberg, B.
|
|
|
34 |
S1 |
p. S97-S98
|
artikel
|
| 244 |
P-74 In vitro experiments on activation of the nrf2 pathway by racanisodamine to alleviate radiation-induced cellular senescence
|
Yin, H.
|
|
|
34 |
S1 |
p. S40
|
artikel
|
| 245 |
P-152 Involvement of FOXM1-regulated histone chaperone ASF1B in gastric cancer growth
|
Zhao, Z.
|
|
|
34 |
S1 |
p. S69
|
artikel
|
| 246 |
P-92 Is preoperative chemosensitivity associated with improved outcomes in locally advanced gastric cancer? A multicentric retrospective real-world study
|
Caleça, T.
|
|
|
34 |
S1 |
p. S46
|
artikel
|
| 247 |
P-12 Is there a risk of cancer in chronic inflammatory bowel disease?
|
Bakkali, K.
|
|
|
34 |
S1 |
p. S17-S18
|
artikel
|
| 248 |
P-26 Is there room for nal-IRI in biliary tract cancer?
|
Merz, V.
|
|
|
34 |
S1 |
p. S22
|
artikel
|
| 249 |
P-177 Italian real world artificial intelligence (AI) based analysis of EaRly-onset COLorEctal cancer: The ERCOLE study
|
Calegari, M.
|
|
|
34 |
S1 |
p. S79
|
artikel
|
| 250 |
P-4 KRAS mutation and survival of rectal cancer in Korea between 2010 and 2015: Analysis of the Collaborative Stage Data of Korean Central Cancer Registry
|
Kim, J.
|
|
|
34 |
S1 |
p. S15
|
artikel
|
| 251 |
P-29 Kyoto classification to correlated gastric cancer and dysplasia
|
Batdelger, A.
|
|
|
34 |
S1 |
p. S23
|
artikel
|
| 252 |
P-91 Landscape of BRAF-V600E mutant colorectal cancer management in Latin America
|
Coutinho, A.
|
|
|
34 |
S1 |
p. S46
|
artikel
|
| 253 |
P-147 Latin American women with gastric adenocarcinoma and ovarian metastasis: Therapeutic approaches and overall survival
|
Calderillo-Ruiz, G.
|
|
|
34 |
S1 |
p. S67
|
artikel
|
| 254 |
P-334 Lenvatinib plus checkpoint inhibitors (ICIs) versus sorafenib plus ICIs as first-line treatment for unresectable hepatocellular carcinoma with Child-Pugh B
|
Ding, X.
|
|
|
34 |
S1 |
p. S131-S132
|
artikel
|
| 255 |
P-128 Liver metastasis affects progression pattern during immune checkpoint inhibitors monotherapy in gastric cancer
|
Motoo, I.
|
|
|
34 |
S1 |
p. S60-S61
|
artikel
|
| 256 |
P-303 Localization of cholangiocarcinoma: Impact on prognosis and clinical management – a single-center study in Albania
|
Sina, M.
|
|
|
34 |
S1 |
p. S122
|
artikel
|
| 257 |
P-407 Locally advanced anal cancer: A single center analysis
|
Mendes, A. Duarte
|
|
|
34 |
S1 |
p. S155
|
artikel
|
| 258 |
P-28 Locally advanced gastric cancer under FLOT – real-world data on efficacy of patients with dMMR
|
Gonçalves, L.
|
|
|
34 |
S1 |
p. S23
|
artikel
|
| 259 |
P-95 Long-term effectiveness results and prognostic predictors for overall survival from CIREL – the real-world multi-centre, observational cohort on irinotecan-eluting transarterial chemoembolization in CRLM
|
Prenen, H.
|
|
|
34 |
S1 |
p. S47
|
artikel
|
| 260 |
P-321 Low dose nivolumab with TKI in advanced HCC: Real world outcomes from India
|
Wisely, J.
|
|
|
34 |
S1 |
p. S128
|
artikel
|
| 261 |
P-52 Lower yield of liquid biopsies for detecting actionable mutations in gastrointestinal malignancies as compared to other solid metastatic cancer types
|
Singh, S.
|
|
|
34 |
S1 |
p. S31
|
artikel
|
| 262 |
P-329 Low expression of CPT1A in colorectal cancer infers favorable prognosis
|
Xu, G.
|
|
|
34 |
S1 |
p. S130
|
artikel
|
| 263 |
P-381 Management of EaRly-onset MetastatIc cOlorectal caNcEr (ERMIONE): A single institution analysis
|
Valente, G.
|
|
|
34 |
S1 |
p. S147
|
artikel
|
| 264 |
P-98 Management of intraductal papillary mucinous neoplasm-associated malignancies in elderly patients
|
Toyokawa, T.
|
|
|
34 |
S1 |
p. S48-S49
|
artikel
|
| 265 |
P-13 Management of metastatic colorectal cancer in patients ≥70 years: A single-center experience
|
Huemer, F.
|
|
|
34 |
S1 |
p. S18
|
artikel
|
| 266 |
P-215 06-methylguanine DNA methyltransferase deficiency and outcomes with CAPTEM in patients with pancreatic neuroendocrine tumours
|
Brage, E. Terán
|
|
|
34 |
S1 |
p. S92
|
artikel
|
| 267 |
P-390 Micronutrient insufficiency after surgery for oesophagogastric neoplasms: A prospective intervention study VITAMin Insufficiency in oesophagogastric Neoplasms or the VITAMIN study
|
van der Velden, A.
|
|
|
34 |
S1 |
p. S150
|
artikel
|
| 268 |
P-43 Minimal residual disease represents a small fraction of ctDNA+ cases undergoing surveillance for colorectal cancer recurrence and may experience subsequent spontaneous ctDNA clearance
|
Fakih, M.
|
|
|
34 |
S1 |
p. S28-S29
|
artikel
|
| 269 |
P-314 mIR-26A and mIR-335-5p as clinical biomarkers in Latin American patients with colon cancer: Preliminary results
|
Carbajal-López, B.
|
|
|
34 |
S1 |
p. S125-S126
|
artikel
|
| 270 |
P-161 MiR181c/d regulates sensitivity to cisplatin/gemcitabine by targeting SIRT1 in cholangiocarcinoma
|
Salati, M.
|
|
|
34 |
S1 |
p. S72
|
artikel
|
| 271 |
P-255 MiR-373-3p inhibits proliferation, invasion and stemness of gastric cancer by targeting CD44
|
Zhang, B.
|
|
|
34 |
S1 |
p. S105-S106
|
artikel
|
| 272 |
P-160 Mismatch repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy
|
Pretta, A.
|
|
|
34 |
S1 |
p. S72
|
artikel
|
| 273 |
P-291 Missing colorectal liver metastases after neoadjuvant chemotherapy: Can we improve the prognosis?
|
Fernandez de Sevilla, E.
|
|
|
34 |
S1 |
p. S118
|
artikel
|
| 274 |
P-233 Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study, updated with new data
|
Ioannou, S.
|
|
|
34 |
S1 |
p. S98
|
artikel
|
| 275 |
P-182 Multicenter real-world data of treatment with NALIRI plus 5FU/LV in advanced Spanish pancreatic cancer
|
Gallego, R. Álvarez
|
|
|
34 |
S1 |
p. S80-S81
|
artikel
|
| 276 |
P-312 Multiplexed immunohistochemistry and digital histopathology-based immunoscore predict survival for colorectal cancer
|
Zhou, S.
|
|
|
34 |
S1 |
p. S125
|
artikel
|
| 277 |
P-77 Multisite intratumoral chemotherapy improves treatment outcome in a murine model with pancreatic ductal adenocarcinoma
|
Epelbaum, R.
|
|
|
34 |
S1 |
p. S41
|
artikel
|
| 278 |
P-9 Multivariate prognostic models for patients with stage I and II colon carcinoma: A STROBE-compliant retrospective cohort study
|
Onate-Ocana, L.
|
|
|
34 |
S1 |
p. S16-S17
|
artikel
|
| 279 |
P-190 NALIRIFOX (iposomal irinotecan + 5-fluorouracil/feucovorin + oxaliplatin) versus FOLFOX [5-fluorouracil/leucovorin + oxaliplatin] as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall survival
|
O'Reilly, E.
|
|
|
34 |
S1 |
p. S83
|
artikel
|
| 280 |
P-129 Necessity and safety of simultaneous cholecystectomy during gastric surgery in patients with asymptomatic cholelithiasis: A systematic review and meta-analysis
|
Jiang, T.
|
|
|
34 |
S1 |
p. S61
|
artikel
|
| 281 |
P-336 Neoadjuvant chemotherapy of the mFOLFIRINOX in the treatment of resectable pancreatic cancer
|
Kantieva, D.
|
|
|
34 |
S1 |
p. S132
|
artikel
|
| 282 |
P-50 Neoadjuvant chemotherapy then chemoradiotherapy followed by surgery in locally advanced rectal cancer. A single-centre analysis
|
Prince, S.
|
|
|
34 |
S1 |
p. S30-S31
|
artikel
|
| 283 |
P-60 Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: A single-arm phase II clinical trial
|
Liu, T.
|
|
|
34 |
S1 |
p. S35
|
artikel
|
| 284 |
P-413 NER repair system and predisposition to hereditary colorectal cancer: ERCC1 novel mutation in a Tunisian family
|
Jaballah-Gabteni, A.
|
|
|
34 |
S1 |
p. S157
|
artikel
|
| 285 |
P-241 Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil plus bevazicumab: Final analysis from a Danish randomised study
|
Pfeiffer, P.
|
|
|
34 |
S1 |
p. S101
|
artikel
|
| 286 |
P-175 Next-generation sequencing in colorectal cancer patients: Characterization and prognostic implications
|
Longo, F.
|
|
|
34 |
S1 |
p. S78
|
artikel
|
| 287 |
P-326 Noninvasive diagnostic models based on CT scans for differentiating solitary pulmonary metastasis in colorectal cancer patients by artificial intelligence: A multicenter study
|
Gao, X.
|
|
|
34 |
S1 |
p. S129
|
artikel
|
| 288 |
P-219 Non-operative management of localized mismatch repair deficient colon cancer: A real-world perspective
|
Chakrabarti, S.
|
|
|
34 |
S1 |
p. S93
|
artikel
|
| 289 |
P-386 Novel data visualization and unsupervised machine learning techniques to support optimal management of toxicity profiles of encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer
|
Wasan, H.
|
|
|
34 |
S1 |
p. S148-S149
|
artikel
|
| 290 |
P-308 Novel gold (III) TGS121 complex selectively affects proteostasis of Ras-hyperactivated colorectal cancer cells via a shift in signaling pathways
|
Lipiec, S.
|
|
|
34 |
S1 |
p. S124
|
artikel
|
| 291 |
P-271 Novel molecular classification of colorectal cancer by using immunohistochemistry in Pakistani population and survival
|
Mangi, F.
|
|
|
34 |
S1 |
p. S111
|
artikel
|
| 292 |
P-223 Nutritional screening and assessment in patients followed for gastrointestinal cancers in west of Algeria
|
Djounidi, A.
|
|
|
34 |
S1 |
p. S94-S95
|
artikel
|
| 293 |
P-75 Nutritional status and chemotherapy toxicity in elderly patients with gastrointestinal cancer
|
Miraoui, D.
|
|
|
34 |
S1 |
p. S40
|
artikel
|
| 294 |
P-421 Obesity – factor of hepatocarcinogenesis in chronic hepatitis C
|
Marilena, S.
|
|
|
34 |
S1 |
p. S160
|
artikel
|
| 295 |
P-55 Obstructive gastric and gastroesophageal junction cancer predicts worse survival in curatively treated patients – analysis from a tertiary care center in India
|
Simha, A.
|
|
|
34 |
S1 |
p. S32
|
artikel
|
| 296 |
P-356 Oesophageal cancer standing in Morocco from diagnosis to treatments
|
Tafenzi, H. Abdelilah
|
|
|
34 |
S1 |
p. S139
|
artikel
|
| 297 |
P-103 Operative risk factors for clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy: A prospective multicenter cohort study
|
Omar, M.
|
|
|
34 |
S1 |
p. S50
|
artikel
|
| 298 |
P-254 Outcomes and prognostic factors of resected pancreatic ductal adenocarcinoma in Saudi Arabia
|
Alshammari, K.
|
|
|
34 |
S1 |
p. S105
|
artikel
|
| 299 |
P-266 Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
|
Cowzer, D.
|
|
|
34 |
S1 |
p. S109
|
artikel
|
| 300 |
P-174 Outcomes in local gastric cancer resected without neoadjuvant therapy: A descriptive study
|
Buscarons, E. Bujons
|
|
|
34 |
S1 |
p. S77-S78
|
artikel
|
| 301 |
P-48 Outcomes of early gall bladder cancer (GBCA): A retrospective analysis from a tertiary care centre in India
|
Ghosh, J.
|
|
|
34 |
S1 |
p. S30
|
artikel
|
| 302 |
P-409 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving atezolizumab
|
Esmail, A.
|
|
|
34 |
S1 |
p. S156
|
artikel
|
| 303 |
P-353 Outcomes of phosphorus-32 microparticle intratumoural implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinoma
|
Lim, A.
|
|
|
34 |
S1 |
p. S138
|
artikel
|
| 304 |
P-71 Overcoming chemoresistance in patients with metastatic colorectal cancer using hepatic arterial infusion
|
Cherchenko, K.
|
|
|
34 |
S1 |
p. S39
|
artikel
|
| 305 |
P-94 Overview of clinicopathological and prognostic factors for long-term survivors of pancreatic cancer from a multicenter study of 532 patients
|
Garajová, I.
|
|
|
34 |
S1 |
p. S47
|
artikel
|
| 306 |
P-261 Oxaliplatine plus fluoropyrimidine versus fluoropyrimidine monotherapy as adjuvant treatment for stage III resected colorectal cancer (CRC) in older population, a single centre experience
|
Ruiz-Gutierrez, I.
|
|
|
34 |
S1 |
p. S107-S108
|
artikel
|
| 307 |
P-296 Pain management in pancreatic cancer
|
Tani, S. Chaibdra
|
|
|
34 |
S1 |
p. S120
|
artikel
|
| 308 |
P-411 Pancreatic cancer oral inverse agonist of RORgT receptor targets primary cancer cells and alters inflammatory mediators of the tumor microenvironment
|
Johnson, D.
|
|
|
34 |
S1 |
p. S157
|
artikel
|
| 309 |
P-203 Pathological evaluation of the therapeutic effect of argon plasma coagulation in gastric low grade dysplasia
|
Jeong, K.
|
|
|
34 |
S1 |
p. S88
|
artikel
|
| 310 |
P-59 Patient and caregiver experiences of gastric cancer: Real-world insights from social media
|
Bernacki, K.
|
|
|
34 |
S1 |
p. S35
|
artikel
|
| 311 |
P-272 Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune checkpoint inhibitor (ICI) therapy
|
Keane, F.
|
|
|
34 |
S1 |
p. S111-S112
|
artikel
|
| 312 |
P-208 Pattern of recurrence in patients undergoing curative treatment for gastric cancer – results from a tertiary care center in India
|
Simha, A.
|
|
|
34 |
S1 |
p. S89-S90
|
artikel
|
| 313 |
P-111 PD1 and LAG3 inhibition as second+ line treatment after EGFR antibody-containing therapy in RAS/BRAF wildtype, MMRp metastatic colorectal cancer
|
Mencel, J.
|
|
|
34 |
S1 |
p. S53-S54
|
artikel
|
| 314 |
P-391 Perioperative chemotherapy for operable gastro-esophageal or gastric cancer: Anthracycline triplets versus FLOT
|
van der Zijden, C.
|
|
|
34 |
S1 |
p. S150
|
artikel
|
| 315 |
P-375 Perioperative FLOT in locally advanced and gastroesophageal junction cancer: A real-word experience in Argentina
|
Aymar, M.
|
|
|
34 |
S1 |
p. S145
|
artikel
|
| 316 |
P-137 Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
|
Harding, J.
|
|
|
34 |
S1 |
p. S63-S64
|
artikel
|
| 317 |
P-130 Phylogeography origin of Helicobacter pylori isolated from Colombian patients with different risk of gastric cancer
|
Guzman, K.
|
|
|
34 |
S1 |
p. S61
|
artikel
|
| 318 |
P-423 Place of CEA in the evaluation of the treatment of metastatic colon cancer
|
El Hakim, B. Abdelkader
|
|
|
34 |
S1 |
p. S160
|
artikel
|
| 319 |
P-357 Place of CEA in the evaluation of the treatment of metastatic colon cancer
|
El Hakim, B. Abdelkader
|
|
|
34 |
S1 |
p. S140
|
artikel
|
| 320 |
P-6 Postoperative anastomotic leakage following minimally invasive esophagectomy for esophageal carcinoma: A single center retrospective analysis
|
Kariyawasam, M.
|
|
|
34 |
S1 |
p. S15-S16
|
artikel
|
| 321 |
P-221 Prediction of colon cancer recurrence based on proteomic biomarkers
|
Cameselle-Garcia, S.
|
|
|
34 |
S1 |
p. S94
|
artikel
|
| 322 |
P-162 Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): A retrospective exploratory study
|
Huang, J.
|
|
|
34 |
S1 |
p. S73
|
artikel
|
| 323 |
P-83 Preoperative endoscopic biliary drainage procedures may affect intrahepatic recurrence of cholangiocarcinoma after surgical resection
|
Kim, J.
|
|
|
34 |
S1 |
p. S43
|
artikel
|
| 324 |
P-140 Prognoctic value of tumor infiltration lymphocytes (Tils) and gastric carcinoma
|
Lajnef, I.
|
|
|
34 |
S1 |
p. S65
|
artikel
|
| 325 |
P-10 Prognostic and predictive relevance of MAP17 in pancreatic cancer
|
Pérez, J. Martínez
|
|
|
34 |
S1 |
p. S17
|
artikel
|
| 326 |
P-179 Prognostic and predictive value of CEA before initiation of therapy in the XELAVIRI trial
|
Alig, A.
|
|
|
34 |
S1 |
p. S79-S80
|
artikel
|
| 327 |
P-213 Prognostic biomarkers in patients with oesophago-gastric cancer treated with immunotherapy
|
Brage, E. Terán
|
|
|
34 |
S1 |
p. S91
|
artikel
|
| 328 |
P-53 Prognostic factors in metastatic pancreatic carcinoma: A multivariate analysis and predictive score of survival
|
Bengueddach, A.
|
|
|
34 |
S1 |
p. S31-S32
|
artikel
|
| 329 |
P-90 Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment
|
Vetere, G.
|
|
|
34 |
S1 |
p. S45
|
artikel
|
| 330 |
P-365 Prognostic impact of mutations and allele frequency of KRAS in metastatic colorectal cancer: A retrospective analysis of a cancer center in Brazil
|
Viana, R.
|
|
|
34 |
S1 |
p. S142
|
artikel
|
| 331 |
P-310 Prognostic impact of neutrophil-to-lymphocyte ratio and malnutrition in de novo metastatic pancreatic cancer
|
Freitas, M.
|
|
|
34 |
S1 |
p. S124
|
artikel
|
| 332 |
P-100 Prognostic implications of liver lesion number in intrahepatic cholangiocarcinoma with liver metastases: A ten-year cohort study
|
Chan, B.
|
|
|
34 |
S1 |
p. S49
|
artikel
|
| 333 |
P-289 Prognostic role of clinical and pathobiological factors in patients with locally advanced gastric and esophagogastric junction cancers: Potential implications in the post-operative strategy
|
Liscia, N.
|
|
|
34 |
S1 |
p. S117-S118
|
artikel
|
| 334 |
P-18 Prognostic significance of microRNAs miR-497-5p and miR-548b-5p for predicting hepatitis B virus-related hepatocellular carcinoma recurrence after curative surgical resection
|
Teng, C.
|
|
|
34 |
S1 |
p. S19-S20
|
artikel
|
| 335 |
P-377 Prognostic stratification of TAS-102 treatment
|
Goncalves, M.
|
|
|
34 |
S1 |
p. S146
|
artikel
|
| 336 |
P-270 Prognostic value of RAS status in Tunisian patients with colorectal cancer
|
Ammous, M.
|
|
|
34 |
S1 |
p. S111
|
artikel
|
| 337 |
P-222 Prognostic value of skeletal muscle area at diagnosis in patients with metastatic colorectal cancer: A single institution experience
|
Rios, M.
|
|
|
34 |
S1 |
p. S94
|
artikel
|
| 338 |
P-300 Progression-free survival in patients with metastatic colorectal cancer treated with maintenance therapy with bevacizumab adjusted by sideness in a third level hospital in Mexico City
|
Viveros, E.
|
|
|
34 |
S1 |
p. S121
|
artikel
|
| 339 |
P-397 Progression-free survival with maintenance therapy with fluoropyrimidine in patients with advanced gastric and gastroesophageal junction cancer in a third level hospital in Mexico City
|
Pimentel, A.
|
|
|
34 |
S1 |
p. S152
|
artikel
|
| 340 |
P-342 Prospective, observational study evaluating the effectiveness and safety of aflibercept plus FOLFIRI in metastatic colorectal cancer (mCRC) according to Polish reimbursement criteria
|
Durbajlo, A.
|
|
|
34 |
S1 |
p. S134
|
artikel
|
| 341 |
P-251 Prospective validation of the Asian Pacific Colorectal Screening (APCS) score to detect colorectal neoplasia among Mexican subjects undergoing screening colonoscopy
|
Meneses-Medina, M.
|
|
|
34 |
S1 |
p. S104
|
artikel
|
| 342 |
P-344 Proteomic identifies heterogeneity of AFP-negative hepatocellular carcinoma
|
Song, P.
|
|
|
34 |
S1 |
p. S135
|
artikel
|
| 343 |
P-20 Pseudoglandular pattern in hepatocellular neoplasms and its diagnostic value with cytokeratin immunostain
|
Zhu, L.
|
|
|
34 |
S1 |
p. S20
|
artikel
|
| 344 |
P-149 QUATTRO-II: A multicenter randomized trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Efficacy and safety analysis
|
Kotaka, M.
|
|
|
34 |
S1 |
p. S68
|
artikel
|
| 345 |
P-25 Questionnaire-assisted surveillance strategy for patients with precancerous conditions of gastric cancer
|
He, S.
|
|
|
34 |
S1 |
p. S22
|
artikel
|
| 346 |
P-24 Racanisodamine attenuates radiation-induced lung injury by activating the NRF2 pathway: In vivo studies
|
Wang, W.
|
|
|
34 |
S1 |
p. S22
|
artikel
|
| 347 |
P-30 Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy – final results of the phase II RE-ExPEL study
|
Goetze, T.
|
|
|
34 |
S1 |
p. S23-S24
|
artikel
|
| 348 |
P-228 Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107
|
Morris, V.
|
|
|
34 |
S1 |
p. S96
|
artikel
|
| 349 |
P-394 RAS/ BRAF molecular profile in metastatic versus non-metastatic colorectal cancer
|
Douik, H.
|
|
|
34 |
S1 |
p. S151
|
artikel
|
| 350 |
P-382 RAS/RAF mutation status in Algerian patients with metastatic colorectal cancer (mCRC) and impact of the primary site on clinical and prognostic outcomes
|
Djounidi, A.
|
|
|
34 |
S1 |
p. S147
|
artikel
|
| 351 |
P-260 Real-life clinical experience of patients with metastatic GISTs treated first-line with imatinib for a decade
|
Samblás, V. García
|
|
|
34 |
S1 |
p. S107
|
artikel
|
| 352 |
P-238 Real-life data on the use of FLOT4 and CROSS for patients with esophageal, gastric or gastroesophageal junction adenocarcinoma
|
López, I. Solana
|
|
|
34 |
S1 |
p. S100
|
artikel
|
| 353 |
P-3 Real-world dosing patterns of regorafenib in patients with metastatic colorectal cancer in Spain: The RE-SEARCH study
|
Muñoz, A. López
|
|
|
34 |
S1 |
p. S14-S15
|
artikel
|
| 354 |
P-277 Real-world efficacy, safety, and impact of the GIPI score of nivolumab in advanced esophageal squamous cell carcinoma (ESCC) refractory or intolerant to prior chemotherapy in European population: The EPIC trial
|
Lago, N. Martínez
|
|
|
34 |
S1 |
p. S113-S114
|
artikel
|
| 355 |
P-274 Real-world evidence for dose reduced preoperative chemotherapy in the older population with resectable gastroesophageal cancer
|
Skjoldbirk, J.
|
|
|
34 |
S1 |
p. S112
|
artikel
|
| 356 |
P-412 Real--world evidence of gastrointestinal stromal tumors (GIST) patients with second primary malignant tumors (SPMT)
|
González, M. Contreras
|
|
|
34 |
S1 |
p. S157
|
artikel
|
| 357 |
P-288 Real-world experience of immune checkpoint inhibitors in MSI-H/dMMR metastatic colorectal cancer in a tertiary cancer center in Saudi Arabia
|
Ajina, R.
|
|
|
34 |
S1 |
p. S117
|
artikel
|
| 358 |
P-192 Real-world experience with trifluridine/tipiracil on metastatic colorectal cancer in a third level hospital
|
Rodríguez, D. Rosero
|
|
|
34 |
S1 |
p. S84
|
artikel
|
| 359 |
P-107 Real-world screening and consensus based on practices and evidence (SCOPE) in gastrointestinal cancers: Practice patterns in metastatic pancreatic cancer
|
Prager, G.
|
|
|
34 |
S1 |
p. S52
|
artikel
|
| 360 |
P-209 Real-world study of durvalumab and chemotherapy in Indian patients with advanced biliary tract cancers
|
Muddu, V.
|
|
|
34 |
S1 |
p. S90
|
artikel
|
| 361 |
P-380 Real-world survival outcome in gastric cancer in a resource limited setting – an Indian experience
|
Kumar, R.
|
|
|
34 |
S1 |
p. S147
|
artikel
|
| 362 |
P-63 Real-world UK retrospective multi-centre review of the use of G-CSF in the prevention of chemotherapy-induced neutropenia in patients with CRC receiving trifluridine/tipiracil
|
Purcell, I.
|
|
|
34 |
S1 |
p. S36
|
artikel
|
| 363 |
P-309 Recent epidemiological data on pancreatic cancer in Albania
|
Sina, M.
|
|
|
34 |
S1 |
p. S124
|
artikel
|
| 364 |
P-387 Rechallenge with anti-EGFR antibodies in metastatic colorectal cancer: A single center analysis
|
Mendes, A. Duarte
|
|
|
34 |
S1 |
p. S149
|
artikel
|
| 365 |
P-325 Reconsidering the TNM stage in non-metastatic colorectal cancer according to the survival paradox
|
Zheng, P.
|
|
|
34 |
S1 |
p. S129
|
artikel
|
| 366 |
P-355 Recruitment of gastrointestinal cancer patients via PLATON Network: An interactive precision oncology platform
|
Al-Batran, S.
|
|
|
34 |
S1 |
p. S139
|
artikel
|
| 367 |
P-403 Rectal cancer in young patients – single center experience
|
Patel, V.
|
|
|
34 |
S1 |
p. S154
|
artikel
|
| 368 |
P-2 Re-evaluating the trends in colon cancer
|
Shukla, P.
|
|
|
34 |
S1 |
p. S14
|
artikel
|
| 369 |
P-246 Removal of intrahepatic bile duct stone could reduce the risk of cholangiocarcinoma, regardless of recurrence of stone
|
Kim, T.
|
|
|
34 |
S1 |
p. S102-S103
|
artikel
|
| 370 |
P-11 Response of pancreatic ductal adenocarcinoma to gemcitabine using a human organotypic slice culture model
|
Chang, J.
|
|
|
34 |
S1 |
p. S17
|
artikel
|
| 371 |
P-138 Retrospective analysis of management of BRAF V600E mutated colorectal cancer in a single institution
|
Velasco, R. Pérez
|
|
|
34 |
S1 |
p. S64
|
artikel
|
| 372 |
P-362 Retrospective analysis of metastatic colorectal cancer based on clinical cancer registry data. Tumor biology, treatment, and outcome
|
Surovtsova, I.
|
|
|
34 |
S1 |
p. S141
|
artikel
|
| 373 |
P-64 Retrospective analysis of radical surgeries on deficient mismatch repair metastatic colorectal cancer with durable partial responses under checkpoint inhibitors. Is radical surgery still necessary?
|
Torrado, C.
|
|
|
34 |
S1 |
p. S36-S37
|
artikel
|
| 374 |
P-333 Retrospective analysis of second-line chemotherapy after Folfirinox failure in advanced pancreatic cancer
|
Chikhareva, Y.
|
|
|
34 |
S1 |
p. S131
|
artikel
|
| 375 |
P-66 Retrospective analysis of the use of total neoadjuvant therapy in high-risk locally advanced rectal cancer in a single institution
|
Torrado, C.
|
|
|
34 |
S1 |
p. S37
|
artikel
|
| 376 |
P-295 Retrospective cohort study of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer: A real-world data from 4 hospitals in Portugal
|
Menezes, M.
|
|
|
34 |
S1 |
p. S119-S120
|
artikel
|
| 377 |
P-287 Retrospective real-world data study using natural language processing to describe treatment sequence and clinicopathological patterns in patients with metastatic colorectal cancer in five Spanish institutions
|
García, R. Vera
|
|
|
34 |
S1 |
p. S117
|
artikel
|
| 378 |
P-323 Rising proportion of young individuals with rectal cancer in Mexico: Analysis in a cancer center
|
Campos-Gomez, S.
|
|
|
34 |
S1 |
p. S128
|
artikel
|
| 379 |
P-32 Risk factors for early recurrence after radical gastrectomy followed by adjuvant chemotherapy for stage II or III gastric cancer: A multicenter, retrospective study
|
Yagi, S.
|
|
|
34 |
S1 |
p. S24-S25
|
artikel
|
| 380 |
P-405 Risk of multiple primary GIT malignancies in patients with primary pancreatic cancer
|
Aly, A.
|
|
|
34 |
S1 |
p. S155
|
artikel
|
| 381 |
P-276 Robust and cost effective in-vivo CAM models for drug combination study in colorectal cancer during COVID-19 pandemic
|
Aslam, R.
|
|
|
34 |
S1 |
p. S113
|
artikel
|
| 382 |
P-399 Role of Ki67 expression as a prognostic marker in advanced colorectal cancer
|
Wider, D.
|
|
|
34 |
S1 |
p. S153
|
artikel
|
| 383 |
P-281 Safety analysis and preliminary clinical results of REPROGRAM-01 phase II study evaluating regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer
|
Borg, C.
|
|
|
34 |
S1 |
p. S115
|
artikel
|
| 384 |
P-419 Safety and effectiveness analysis of neoadjuvant chemoradiation plus consolidative chemotherapy with concurrent anti-PD-1 therapy in mid-low locally advanced rectal cancer
|
Liu, X.
|
|
|
34 |
S1 |
p. S159
|
artikel
|
| 385 |
P-226 Safety and efficacy of combined trans-arterial radioembolization and systemic therapy for advanced hepatocellular carcinoma
|
Alshammari, K.
|
|
|
34 |
S1 |
p. S95-S96
|
artikel
|
| 386 |
P-361 Safety and efficacy of short cetuximab infusion for patients with metastatic colorectal cancer
|
Alshammari, K.
|
|
|
34 |
S1 |
p. S141
|
artikel
|
| 387 |
P-93 Safety and feasibility of irradiation and nivolumab in esophageal cancer – a phase I/II study
|
Hjortland, G.
|
|
|
34 |
S1 |
p. S46-S47
|
artikel
|
| 388 |
P-84 Safety of robotic total gastrectomy in comparisons of laparoscopic total gastrectomy: A retrospective study in a high volume gastric cancer center
|
Kang, H.
|
|
|
34 |
S1 |
p. S43
|
artikel
|
| 389 |
P-322 Sarcopenia predicts outcomes in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab: A multicenter cohort study
|
Nam, H.
|
|
|
34 |
S1 |
p. S128
|
artikel
|
| 390 |
P-338 Second-line treatment with modified FOLFIRINOX in patients with pancreatic adenocarcinoma who have failed first-line treatment with gemcitabine and nab-paclitaxel
|
McSweeney, T.
|
|
|
34 |
S1 |
p. S133
|
artikel
|
| 391 |
P-307 Serial ctDNA monitoring during immunotherapy (IO) in patients (pts) with MSI-H/dMMR advanced colorectal cancer (CRC)
|
Somer, B.
|
|
|
34 |
S1 |
p. S123
|
artikel
|
| 392 |
P-143 Serum metabolomic identifies new diagnostic biomarkers for AFP-negative hepatocellular carcinoma
|
Bian, S.
|
|
|
34 |
S1 |
p. S65-S66
|
artikel
|
| 393 |
P-124 SHP-2 deficiency in myeloid cells promotes metastasis of esophageal carcinoma via increasing cathepsins and inflammatory factor secretion
|
Li, Q.
|
|
|
34 |
S1 |
p. S58
|
artikel
|
| 394 |
P-234 Significance of high-risk factors other than lymph node metastasis on impact of prognosis in stage II-II colon cancer: Multi-center retrospective cohort study
|
Kim, I.
|
|
|
34 |
S1 |
p. S98-S99
|
artikel
|
| 395 |
P-253 Single agent immunotherapy in advanced oesophago-gastric (OG) cancer: An option for frail patients
|
Patel, G.
|
|
|
34 |
S1 |
p. S105
|
artikel
|
| 396 |
P-81 Single-center real-world experience from 18 consecutive cases treated with durvalumab in combination with chemotherapy for advanced biliary tract cancer
|
Zhang, D.
|
|
|
34 |
S1 |
p. S42
|
artikel
|
| 397 |
P-378 Single institute experience of peri-operative FLOT chemotherapy
|
Bansal, V.
|
|
|
34 |
S1 |
p. S146
|
artikel
|
| 398 |
P-402 Six-months CA19.9 velocity as a predictive factor for relapse-free survival after curative pancreasectomy in pancreatic cancer
|
Cesario, S.
|
|
|
34 |
S1 |
p. S154
|
artikel
|
| 399 |
P-363 Skin rash as a predictor of tumor response to EGFR inhibitors in advanced colorectal cancer
|
Duarte, T.
|
|
|
34 |
S1 |
p. S141-S142
|
artikel
|
| 400 |
P-345 SOX-2 promotes epithelial-to-mesenchymal transition by modulating SLUG expression in esophageal squamous cells
|
Jayaraman, S.
|
|
|
34 |
S1 |
p. S135
|
artikel
|
| 401 |
P-188 Spatial genomics identifies prognostic factors for colorectal cancer
|
Gruber, S.
|
|
|
34 |
S1 |
p. S82-S83
|
artikel
|
| 402 |
P-267 Spatially resolved detection of premalignant lesions and immune-infiltration in gastric endoscopic biopsies using multiplexed immunofluorescence and correlation with OLGA/OLGIM assessment
|
Villarroel-Espindola, F.
|
|
|
34 |
S1 |
p. S110
|
artikel
|
| 403 |
P-220 S-1 plus oxaliplatin versus capecitabine plus oxaliplatin chemotherapy in the treatment of patients with metastatic colorectal cancer: A meta-analysis
|
Lalusis, J.
|
|
|
34 |
S1 |
p. S94
|
artikel
|
| 404 |
P-61 STAMBP promoted the development of inflammation-associated colorectal cancer through SP1 mediating TUFT1 transcription
|
Yang, Y.
|
|
|
34 |
S1 |
p. S35-S36
|
artikel
|
| 405 |
P-49 Stereotactic body radiotherapy (SBRT) for liver metastasis. Institutional experience
|
Merino, M. Vera
|
|
|
34 |
S1 |
p. S30
|
artikel
|
| 406 |
P-284 Stereotactic body radiotherapy (SBRT) for liver metastasis of colorectal and anal cancer patients: Clinical outcomes of a single centre experience
|
Martin-Cullell, B.
|
|
|
34 |
S1 |
p. S116
|
artikel
|
| 407 |
P-205 Streamlining the diagnostic pathway for Lynch syndrome in colorectal cancer patients: A ten-year experience in a single Italian center
|
Puccini, A.
|
|
|
34 |
S1 |
p. S88-S89
|
artikel
|
| 408 |
P-305 Surgery or endoscopy for 'high-risk' early esophageal cancer: Prospective observational study including detailed analysis of lymph node involvement
|
Hugova, K.
|
|
|
34 |
S1 |
p. S123
|
artikel
|
| 409 |
P-216 Surgical safety and oncological outcomes of laparoscopic liver resection for colorectal cancer liver metastasis in the Ukrainian state center
|
Rozhkova, V.
|
|
|
34 |
S1 |
p. S92-S93
|
artikel
|
| 410 |
P-189 Surrogate endpoints in advanced gastroesophageal cancer: A systematic review and meta-analysis of phase III clinical trials
|
Veas, J.
|
|
|
34 |
S1 |
p. S83
|
artikel
|
| 411 |
P-155 Surufatinib plus doublet (FOLFOX/FOLFIRI) or triplet (FOLFOXIRI) chemotherapy as second-line therapy in metastatic colorectal cancer (mCRC): First-stage results of a randomized, open-label phase II trial
|
Lin, R.
|
|
|
34 |
S1 |
p. S70
|
artikel
|
| 412 |
P-245 Survival after minimally invasive vs open surgery for pancreatic adenocarcinoma
|
Topal, B.
|
|
|
34 |
S1 |
p. S102
|
artikel
|
| 413 |
P-176 Survival benefits of conversion surgery for stage IV gastric cancer patients treated with anti-PD-1 antibody and chemotherapy and/or targeted therapy
|
Liang, H.
|
|
|
34 |
S1 |
p. S78
|
artikel
|
| 414 |
P-278 Survival impact and predictive scores for thrombosis associated with pancreatic ductal adenocarcinoma (PDAC)
|
Romano, A.
|
|
|
34 |
S1 |
p. S114
|
artikel
|
| 415 |
P-302 Survival impact of fluoropyrimidine dose adjustment in DPD deficient colorectal cancer patients: A single center experience
|
Perez, D. Martinez
|
|
|
34 |
S1 |
p. S122
|
artikel
|
| 416 |
P-404 Survival outcomes and prognostic factors in high risk locally advanced rectal cancers (LARC) undergoing concurrent capecitabine and long course radiation (Cape – RT) – results of a large cohort study
|
Yallala, M. Reddy
|
|
|
34 |
S1 |
p. S154-S155
|
artikel
|
| 417 |
P-187 Targeting glutamine metabolism and EGFR in RAS wildtype colorectal cancer
|
Ciombor, K.
|
|
|
34 |
S1 |
p. S82
|
artikel
|
| 418 |
P-158 The algorithm of esophagectomy technique selection in surgical treatment of squamous cell carcinoma and adenocarcinoma of esophagus
|
Levchenko, E.
|
|
|
34 |
S1 |
p. S71
|
artikel
|
| 419 |
P-15 The challenges in colorectal cancer management in Georgia
|
Kopadze, S.
|
|
|
34 |
S1 |
p. S18-S19
|
artikel
|
| 420 |
P-34 The changing risk of hospitalisation, intensive care admission and death due to COVID-19 in patients with gastrointestinal cancer in the UK
|
Tilby, M.
|
|
|
34 |
S1 |
p. S25
|
artikel
|
| 421 |
P-348 The contribution of circulating tumor cells’ gene expression in treatment response
|
Apostolou, P.
|
|
|
34 |
S1 |
p. S136
|
artikel
|
| 422 |
P-264 The effect of preoperative imatinib therapy in gastrointestinal stromal tumors: A multicenter study
|
Mu, M.
|
|
|
34 |
S1 |
p. S108-S109
|
artikel
|
| 423 |
P-367 The frequency and pattern of metachronous recurrence after endoscopic submucosal dissection for dysplasias and adenocarcinoma of stomach
|
Seo, Y.
|
|
|
34 |
S1 |
p. S142-S143
|
artikel
|
| 424 |
P-45 The homeobox protein VentX mediates therapeutic effects of 5-fluorouracil against colorectal cancer
|
Zhu, A.
|
|
|
34 |
S1 |
p. S29
|
artikel
|
| 425 |
P-343 The impact of genomic alterations on response rate and survival outcomes in advanced BTC patients who receive cisplatin/gemcitabine plus durvalumab in clinical practice
|
Rimini, M.
|
|
|
34 |
S1 |
p. S135
|
artikel
|
| 426 |
P-415 The importance of RAS and BRAF in metastatic colorectal cancer – real-world evidence from North-East Romania
|
Afrasanie, V.
|
|
|
34 |
S1 |
p. S158
|
artikel
|
| 427 |
P-170 The MATTERS trial: A first-in-human study of whole-body hyperthermia in advanced solid cancer patients
|
Gorbaslieva, I.
|
|
|
34 |
S1 |
p. S76
|
artikel
|
| 428 |
P-339 The mechanism of DNA methylation-regulated oncogene SERPINE2 in hepatocellular carcinoma metastasis
|
Zhang, S.
|
|
|
34 |
S1 |
p. S133
|
artikel
|
| 429 |
P-292 The Meta-Lung score: Preoperative clinical score in lung-limited metastatic patients with colorectal cancer
|
Ziranu, P.
|
|
|
34 |
S1 |
p. S118-S119
|
artikel
|
| 430 |
P-106 The neoadjuvant rectal (NAR) score application in the context of total neoadjuvant treatment with chemo-immuno-radiation for locally advanced rectal cancer: Data from the phase II Averectal study
|
Chehade, L.
|
|
|
34 |
S1 |
p. S51-S52
|
artikel
|
| 431 |
P-294 The outcome of patients with mismatch repair deficient esophagogastric cancer receiving immunotherapy: A systematic review
|
Karia, R.
|
|
|
34 |
S1 |
p. S119
|
artikel
|
| 432 |
P-232 The predictive factors for identifying gastric cancer in patients with gastric ‘indefinite for neoplasia’ lesions
|
You, H.
|
|
|
34 |
S1 |
p. S98
|
artikel
|
| 433 |
P-392 The prognostic ability of immunoscore in predicting outcomes in patients with localized colon cancer: A systematic review and meta-analysis
|
Padayao, J.
|
|
|
34 |
S1 |
p. S150-S151
|
artikel
|
| 434 |
P-401 The promising role of TGF-βRII mutations and EGFR immunostaining in response to anti-EGFR therapies
|
Jaballah-Gabteni, A.
|
|
|
34 |
S1 |
p. S153
|
artikel
|
| 435 |
P-370 The role of Ca 19-9 in progression, recurrence and survival of borderline resectable pancreatic cancer
|
Almeida, C.
|
|
|
34 |
S1 |
p. S143-S144
|
artikel
|
| 436 |
P-364 The role of chemotherapy in well-differentiated GIT neuroendocrine tumors
|
Ellaithy, A.
|
|
|
34 |
S1 |
p. S142
|
artikel
|
| 437 |
P-33 The role of preoperative immune-chemotherapy in locally advanced resectable gastric cancer with microsatellite instability
|
Sun, H.
|
|
|
34 |
S1 |
p. S25
|
artikel
|
| 438 |
P-65 The role of total neoadjuvant therapy (TNT) in elderly patients with locally advanced rectal cancer: A mono-institutional retrospective study
|
Lo Greco, M.
|
|
|
34 |
S1 |
p. S37
|
artikel
|
| 439 |
P-127 The screening and consensus based on practices and evidence (SCOPE) survey – results of a real-world survey on practice patterns in gastric cancer
|
Smyth, E.
|
|
|
34 |
S1 |
p. S60
|
artikel
|
| 440 |
P-114 The therapeutic potential of nuclear receptor RORy in hepatocellular carcinoma
|
Cools-Lartigue, J.
|
|
|
34 |
S1 |
p. S55
|
artikel
|
| 441 |
P-318 TLE3-AKR1B1 signaling axis participating in the malignant progression of gastrointestinal stromal tumor by regulating galactose metabolism
|
Yin, X.
|
|
|
34 |
S1 |
p. S127
|
artikel
|
| 442 |
P-202 Topical diclofenac in prevention of capecitabine-associated HFS in patients with GI cancers: An exploratory subgroup analysis of the D-ToRCH study
|
Batra, A.
|
|
|
34 |
S1 |
p. S87-S88
|
artikel
|
| 443 |
P-139 Total neoadjuvant therapy for locally advanced rectal cancer: A UK cohort
|
Forster, M.
|
|
|
34 |
S1 |
p. S64
|
artikel
|
| 444 |
P-374 Total neoadjuvant treatment of rectal cancer by MRI-guided radiotherapy
|
De Ridder, M.
|
|
|
34 |
S1 |
p. S145
|
artikel
|
| 445 |
P-19 Toxicity and outcome of definitive chemoradiotherapy for elderly patients with esophageal cancer
|
Iovashvili, A.
|
|
|
34 |
S1 |
p. S20
|
artikel
|
| 446 |
P-384 TP53 protein expression in colorectal cancer
|
Ben Ayed, I.
|
|
|
34 |
S1 |
p. S148
|
artikel
|
| 447 |
P-85 Treatment propensity and the feasibility of cisplatin plus gemcitabine in elderly patients aged ≥ 75 years with biliary tract cancer
|
Lim, K.
|
|
|
34 |
S1 |
p. S43-S44
|
artikel
|
| 448 |
P-290 Treatment sequences and locoregional therapies for patients with carcinoid and refractory carcinoid syndrome. A multicentric cohort analysis
|
Oviedo, A.
|
|
|
34 |
S1 |
p. S118
|
artikel
|
| 449 |
P-126 TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: Substudies in gastric and colorectal cancer
|
Oaknin, A.
|
|
|
34 |
S1 |
p. S59-S60
|
artikel
|
| 450 |
P-193 Tumor burden-related variables in trials of metastatic colorectal cancer
|
Colloca, G.
|
|
|
34 |
S1 |
p. S84
|
artikel
|
| 451 |
P-341 Tumor regression and nodal status to neoadjuvant chemotherapy as a prognostic marker in patients with locally advanced gastric and gastroesophageal cancer
|
Marcisz-Grzanka, K.
|
|
|
34 |
S1 |
p. S134
|
artikel
|
| 452 |
P-196 Tumor response as a predictor of survival for RAS-WT left-sided mCRC administered first-line molecularly targeted drugs: An observational study by the Japanese Society for Cancer of the Colon and Rectum
|
Hirose, T.
|
|
|
34 |
S1 |
p. S85-S86
|
artikel
|
| 453 |
P-99 Tumor treating fields (TTFields) are effective for treatment of gastric cancer cells, boosting the activity of FOLFOX
|
Flint-Brodsly, N.
|
|
|
34 |
S1 |
p. S49
|
artikel
|
| 454 |
P-167 Type 2 diabetes as a predictive and prognostic factor in advanced pancreatic cancer: Preliminary results of the Italian, observational PANCAKE study
|
Nichetti, F.
|
|
|
34 |
S1 |
p. S75
|
artikel
|
| 455 |
P-132 Underrepresentation of racial and ethnic minorities in metastatic colorectal carcinoma clinical trials within the United States
|
Pu, T.
|
|
|
34 |
S1 |
p. S62
|
artikel
|
| 456 |
P-102 Unmet needs of patients during colorectal cancer care and treatment – a qualitative study through an online patient community
|
Samalin, E.
|
|
|
34 |
S1 |
p. S50
|
artikel
|
| 457 |
P-418 Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study
|
Li, Y.
|
|
|
34 |
S1 |
p. S159
|
artikel
|
| 458 |
P-38 Using a machine learning approach to study host-microbiome interactions in early-onset colorectal adenocarcinoma
|
Jayakrishnan, T.
|
|
|
34 |
S1 |
p. S27
|
artikel
|
| 459 |
P-268 Using 16S rRNA gene sequencing to investigate the composition of Fusobacterium-associated microbiota and its impact on outcome in rectal cancer
|
Napoli, S.
|
|
|
34 |
S1 |
p. S110
|
artikel
|
| 460 |
P-154 Using the EVendo score to predict varices and varices needing treatment in hepatocellular carcinoma patients planned for atezolizumab-bevacizumab
|
Toh, C.
|
|
|
34 |
S1 |
p. S70
|
artikel
|
| 461 |
P-214 Utility of “pseudo-adjuvant” chemotherapy (CT) in metastatic colorectal cancer (mCRC): A monocentric multidisciplinary experience
|
Arrivi, G.
|
|
|
34 |
S1 |
p. S92
|
artikel
|
| 462 |
P-400 Validation study of a high-performance whole-blood assay for the detection of colorectal advanced adenomas in average risk population
|
Hosseinian, S.
|
|
|
34 |
S1 |
p. S153
|
artikel
|
| 463 |
P-416 Value of liquid biopsy in taking faster medical decisions in colorectal cancer patients. Its clinical application in an Argentinian cancer institution
|
Muñoz, M.
|
|
|
34 |
S1 |
p. S158
|
artikel
|
| 464 |
P-265 Value of the Glasgow Prognostic Score (GPS) in the prognosis of hospitalised patients with gastrointestinal cancer
|
Peña, J.
|
|
|
34 |
S1 |
p. S109
|
artikel
|
| 465 |
P-89 Vitamin D levels in patients with cholangiocarcinoma: A relevant test
|
Cidon, E. Una
|
|
|
34 |
S1 |
p. S45
|
artikel
|
| 466 |
P-172 VOLTAGE cohort D: Preoperative chemoradiotherapy followed by consolidation nivolumab plus ipilimumab in patients with locally advanced rectal cancer
|
Takahashi, Y.
|
|
|
34 |
S1 |
p. S77
|
artikel
|
| 467 |
P-212 Wild-type gastrointestinal stromal tumors with NTRK gene fusions
|
Zhang, H.
|
|
|
34 |
S1 |
p. S91
|
artikel
|
| 468 |
P-35 Zanzalintinib (XL092) in combination with atezolizumab for previously treated metastatic colorectal cancer
|
Tabernero, J.
|
|
|
34 |
S1 |
p. S25-S26
|
artikel
|
| 469 |
SO-1 A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma
|
Harding, J.
|
|
|
34 |
S1 |
p. S161
|
artikel
|
| 470 |
SO-17 A new risk classification integrating ctDNA, CEA, and pTN stage for DFS prognosis and predictive value for treatment duration in stage III colon cancer
|
Samaille, T.
|
|
|
34 |
S1 |
p. S169
|
artikel
|
| 471 |
SO-11 Bemarituzumab for treatment of previously untreated advanced and/or metastatic gastric and gastroesophageal cancer (GC): Final analysis of a randomized phase 2 trial (FIGHT)
|
Wainberg, Z.
|
|
|
34 |
S1 |
p. S166
|
artikel
|
| 472 |
SO-6 Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group
|
Weiss, L.
|
|
|
34 |
S1 |
p. S164
|
artikel
|
| 473 |
SO-12 CLDN18.2 expression in resectable gastroesophageal cancers: Associated clinical and molecular signatures and impact of neoadjuvant chemotherapy on intratumor heterogeneity
|
Cammarota, A.
|
|
|
34 |
S1 |
p. S166-S167
|
artikel
|
| 474 |
SO-29 Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis
|
Tabernero, J.
|
|
|
34 |
S1 |
p. S174
|
artikel
|
| 475 |
SO-3 Clinical relevance and actionability of BRAF alterations in advanced biliary tract cancer: Preliminary results from the multicenter B-REAL study
|
Niger, M.
|
|
|
34 |
S1 |
p. S162-S163
|
artikel
|
| 476 |
SO-31 Comprehensive genomic profiling of tumor tissue and plasma-circulating tumor DNA in RAS/BRAFV600E wild type metastatic colorectal cancer patients: Initial findings from the CAPRI 2-GOIM trial
|
Martini, G.
|
|
|
34 |
S1 |
p. S175-S176
|
artikel
|
| 477 |
SO-18 ctDNA-guided adjuvant treatment after radical intent treatment of metastatic spread from colorectal cancer is feasible – results from the preplanned interim analysis of the OPTIMISE study
|
Callesen, L.
|
|
|
34 |
S1 |
p. S169-S170
|
artikel
|
| 478 |
SO-7 First-line liposomal irinotecan (nal-IRI), oxaliplatin and S-1 (NASOX) in unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase I/II study
|
Yoo, C.
|
|
|
34 |
S1 |
p. S164
|
artikel
|
| 479 |
SO-28 FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study
|
Antoniotti, C.
|
|
|
34 |
S1 |
p. S173-S174
|
artikel
|
| 480 |
SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
|
Sangro, B.
|
|
|
34 |
S1 |
p. S168
|
artikel
|
| 481 |
SO-5 Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study
|
Hollebecque, A.
|
|
|
34 |
S1 |
p. S163
|
artikel
|
| 482 |
SO-22 Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study
|
Marmorino, F.
|
|
|
34 |
S1 |
p. S171
|
artikel
|
| 483 |
SO-4 Impact of molecular profiling on survival in patients with advanced biliary tract cancers
|
Antoun, L.
|
|
|
34 |
S1 |
p. S163
|
artikel
|
| 484 |
SO-26 Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study
|
De Stefano, A.
|
|
|
34 |
S1 |
p. S172-S173
|
artikel
|
| 485 |
SO-27 Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO
|
Conca, V.
|
|
|
34 |
S1 |
p. S173
|
artikel
|
| 486 |
SO-25 Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO
|
Sunakawa, Y.
|
|
|
34 |
S1 |
p. S172
|
artikel
|
| 487 |
SO-34 Multi-label transcriptional classification of colorectal cancer reflects tumour cell population heterogeneity
|
Medico, E.
|
|
|
34 |
S1 |
p. S177
|
artikel
|
| 488 |
SO-13 Outcomes and a prognostic classifier in 130 patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade
|
Randon, G.
|
|
|
34 |
S1 |
p. S167
|
artikel
|
| 489 |
SO-24 Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase 2 VELO trial
|
Ciardiello, D.
|
|
|
34 |
S1 |
p. S171-S172
|
artikel
|
| 490 |
SO-10 Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification
|
Satoh, T.
|
|
|
34 |
S1 |
p. S165-S166
|
artikel
|
| 491 |
SO-32 Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)
|
Germani, M.
|
|
|
34 |
S1 |
p. S176
|
artikel
|
| 492 |
SO-8 Predictive values of blood-based RNA signature for the FOLFIRINOX/FOLFOX response in advanced pancreatic cancer
|
Piquemal, D.
|
|
|
34 |
S1 |
p. S164-S165
|
artikel
|
| 493 |
SO-16 Proton beam radiotherapy as a valid curative local alternative modality in newly diagnosed hepatocellular carcinoma: Comparative study with radiofrequency ablation
|
Seo, S.
|
|
|
34 |
S1 |
p. S168-S169
|
artikel
|
| 494 |
SO-2 Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial
|
Valle, J.
|
|
|
34 |
S1 |
p. S162
|
artikel
|
| 495 |
SO-14 Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup
|
Vogel, A.
|
|
|
34 |
S1 |
p. S167-S168
|
artikel
|
| 496 |
SO-30 RAS status in circulating-tumor DNA after chemotherapy in RAS-mutant mCRC: The RASMEX study (JACCRO CC-17)
|
Nishina, S.
|
|
|
34 |
S1 |
p. S175
|
artikel
|
| 497 |
SO-33 The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – a post-hoc exploratory analysis of the randomized NORDIC9-study
|
Liposits, G.
|
|
|
34 |
S1 |
p. S176-S177
|
artikel
|
| 498 |
SO-23 The influence of the microbiome on the tumour-immune microenvironment in colorectal cancer
|
Purcell, R.
|
|
|
34 |
S1 |
p. S171
|
artikel
|
| 499 |
SO-20 The landscape of homologous recombination deficiency in colorectal cancer
|
Ahsan, M.
|
|
|
34 |
S1 |
p. S170
|
artikel
|
| 500 |
SO-19 The outcome of resected stage II colon cancer patients with deficient mismatch repair T4 tumors: A National Cancer Database analysis
|
Ahmed, F.
|
|
|
34 |
S1 |
p. S170
|
artikel
|
| 501 |
SO-9 The relationship between primary tumour-infiltrating immune cells and immune activation status of tumour draining lymph nodes in oesophageal cancer patients – results from the UK MRC OE02 trial
|
Kloft, M.
|
|
|
34 |
S1 |
p. S165
|
artikel
|
| 502 |
SO-21 Tumor mutational signatures in early-onset versus average-onset colorectal cancer
|
Lander, E.
|
|
|
34 |
S1 |
p. S170-S171
|
artikel
|
| 503 |
Table of Contents
|
|
|
|
34 |
S1 |
p. iv
|
artikel
|
Tijdschrift beschrijving